EXHIBIT 10.1
EXECUTION VERSION
U.S. $65,000,000
LOAN AGREEMENT
Dated as of August 5, 2008
Amended and Restated as of March 18,
2009
between
COWEN HEALTHCARE ROYALTY PARTNERS,
L.P.,
as Lender,
and
DYAX CORP.,
as Borrower
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
TABLE OF CONTENTS
|
ARTICLE I
|
|
CERTAIN DEFINITIONS
|
|
|
|
|
|
SECTION 1.01.
|
Definitions
|
1
|
|
SECTION 1.02.
|
Interpretation; Headings
|
17
|
|
|
|
|
|
ARTICLE II
|
|
COMMITMENT; DISBURSEMENT; FEES
|
|
|
|
|
|
SECTION 2.01.
|
Commitment to Lend
|
18
|
|
SECTION 2.02.
|
Notice of Borrowing
|
18
|
|
SECTION 2.03.
|
Disbursement
|
18
|
|
SECTION 2.04.
|
Commitment Not Revolving
|
18
|
|
|
|
|
|
ARTICLE III
|
|
REPAYMENT
|
|
|
|
|
|
SECTION 3.01.
|
Amortization
|
18
|
|
SECTION 3.02.
|
Optional Prepayment; Mandatory
Prepayment
|
19
|
|
SECTION 3.03.
|
Illegality
|
19
|
|
|
|
|
|
ARTICLE IV
|
|
INTEREST; EXPENSES
|
|
|
|
|
|
SECTION 4.01.
|
Interest Rate
|
20
|
|
SECTION 4.02.
|
Lockbox Account
|
21
|
|
SECTION 4.03.
|
Interest on Late Payments
|
24
|
|
SECTION 4.04.
|
Initial Expenses
|
24
|
|
SECTION 4.05.
|
Administration and Enforcement
Expenses
|
24
|
|
|
|
|
|
ARTICLE V
|
|
TAXES
|
|
|
|
|
|
SECTION 5.01.
|
Taxes
|
24
|
|
SECTION 5.02.
|
Receipt of Payment
|
26
|
|
SECTION 5.03.
|
Other Taxes
|
26
|
|
SECTION 5.04.
|
Indemnification
|
26
|
|
SECTION 5.05.
|
Loans Treated As Indebtedness
|
26
|
|
SECTION 5.06.
|
Allocation of Issue Price
|
26
|
|
SECTION 5.07.
|
Registered Obligation
|
27
|
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
|
|
|
Page
|
|
|
|
ARTICLE VI
|
|
PAYMENTS; COMPUTATIONS
|
|
|
|
|
|
SECTION 6.01.
|
Making of Payments
|
27
|
|
SECTION 6.02.
|
Setoff or Counterclaim
|
28
|
|
|
|
|
|
ARTICLE VII
|
|
CLOSING DOCUMENTATION
|
|
|
|
|
|
SECTION 7.01.
|
Tranche A Loan Closing
Documentation
|
28
|
|
SECTION 7.02.
|
Tranche B Loan Closing Documentation
|
30
|
|
|
|
|
|
ARTICLE VIII
|
|
REPRESENTATIONS AND WARRANTIES
|
|
|
|
|
|
SECTION 8.01.
|
Representations and Warranties of
Borrower
|
32
|
|
SECTION 8.02.
|
Survival of Representations and
Warranties
|
40
|
|
|
|
|
|
ARTICLE IX
|
|
AFFIRMATIVE COVENANTS
|
|
|
|
|
|
SECTION 9.01.
|
Maintenance of Existence
|
40
|
|
SECTION 9.02.
|
Use of Proceeds
|
40
|
|
SECTION 9.03.
|
Financial Statements and Information
|
40
|
|
SECTION 9.04.
|
Books and Records
|
41
|
|
SECTION 9.05.
|
Inspection Rights; Access
|
41
|
|
SECTION 9.06.
|
Maintenance of Insurance and
Properties
|
42
|
|
SECTION 9.07.
|
Governmental Authorizations
|
42
|
|
SECTION 9.08.
|
Compliance with Laws and Contracts
|
42
|
|
SECTION 9.09.
|
Plan Assets
|
42
|
|
SECTION 9.10.
|
Notices
|
42
|
|
SECTION 9.11.
|
Payment of Taxes
|
43
|
|
SECTION 9.12.
|
Waiver of Stay, Extension or Usury
Laws
|
43
|
|
SECTION 9.13.
|
Additional Covenants of Borrower
|
43
|
|
SECTION 9.14.
|
[*****]
|
43
|
|
SECTION 9.15.
|
Further Assurances
|
44
|
|
|
|
|
|
ARTICLE X
|
|
NEGATIVE COVENANTS
|
|
|
|
|
|
SECTION 10.01.
|
Activities of Borrower
|
44
|
|
SECTION 10.02.
|
Merger; Sale of Assets
|
44
|
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
ii
|
|
|
Page
|
|
|
|
|
|
SECTION 10.03.
|
Liens
|
45
|
|
SECTION 10.04.
|
Investment Company Act
|
46
|
|
SECTION 10.05.
|
Limitation on Additional Indebtedness
|
46
|
|
SECTION 10.06.
|
Limitation on Transactions with Controlled
Affiliates
|
47
|
|
SECTION 10.07.
|
ERISA
|
47
|
|
SECTION 10.08.
|
Restricted Payments
|
48
|
|
|
|
|
|
ARTICLE XI
|
|
EVENTS OF DEFAULT
|
|
|
|
|
|
SECTION 11.01.
|
Events of Default
|
48
|
|
SECTION 11.02.
|
Default Remedies
|
50
|
|
SECTION 11.03.
|
Right of Set-off; Sharing of Set-off
|
50
|
|
SECTION 11.04.
|
Rights Not Exclusive
|
51
|
|
|
|
|
|
ARTICLE XII
|
|
INDEMNIFICATION
|
|
|
|
|
|
SECTION 12.01.
|
Funding Losses
|
51
|
|
SECTION 12.02.
|
Increased Costs
|
52
|
|
SECTION 12.03.
|
Other Losses
|
52
|
|
SECTION 12.04.
|
Assumption of Defense; Settlements
|
53
|
|
|
|
|
|
ARTICLE XIII
|
|
MISCELLANEOUS
|
|
|
|
|
|
SECTION 13.01.
|
Assignments
|
53
|
|
SECTION 13.02.
|
Participations
|
54
|
|
SECTION 13.03.
|
Successors and Assigns
|
55
|
|
SECTION 13.04.
|
Notices
|
55
|
|
SECTION 13.05.
|
Entire Agreement
|
56
|
|
SECTION 13.06.
|
Modification
|
57
|
|
SECTION 13.07.
|
No Delay; Waivers; etc.
|
57
|
|
SECTION 13.08.
|
Severability
|
57
|
|
SECTION 13.09.
|
Determinations
|
57
|
|
SECTION 13.10.
|
Replacement of Note
|
57
|
|
SECTION 13.11.
|
Governing Law
|
57
|
|
SECTION 13.12.
|
Jurisdiction
|
57
|
|
SECTION 13.13.
|
Waiver of Jury Trial
|
58
|
|
SECTION 13.14.
|
Waiver of Immunity
|
58
|
|
SECTION 13.15.
|
Counterparts
|
58
|
|
SECTION 13.16.
|
Limitation on Rights of Others
|
58
|
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
iii
|
|
|
Page
|
|
|
|
|
|
SECTION 13.17.
|
No Partnership
|
58
|
|
SECTION 13.18.
|
Survival
|
58
|
|
SECTION 13.19.
|
Patriot Act Notification
|
58
|
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
iv
Exhibits
|
Exhibit A
|
|
Business Report Format
|
|
Exhibit B
|
|
Form of Tranche B Promissory
Note
|
|
Exhibit C
|
|
Quarterly Report Format
|
|
Exhibit D
|
|
Form of Security Agreement
|
|
Exhibit E
|
|
Form of Notice of Borrowing
|
|
Exhibit F
|
|
Lockbox Instructions
|
|
Exhibit G
|
|
Form of Certificate of Borrower
|
|
Exhibit H
|
|
Form of Edwards, Angell Palmer &
Dodge LLP Opinion
|
|
Exhibit I
|
|
Form of Wolf Greenfield Opinion
|
|
Exhibit J
|
|
Form of Lowrie, Lando & Anastasi,
LLP Opinion
|
|
Exhibit K
|
|
Tranche B Warrant Agreement
|
|
Exhibit L
|
|
Form of Assignment and
Acceptance
|
Schedules
|
Schedule A
|
|
[*****]
|
|
Schedule B
|
|
[*****]
|
|
Schedule C
|
|
[*****]
|
|
Schedule D
|
|
[*****]
|
|
Schedule 8.01(l)
|
|
Indebtedness
|
|
Schedule 8.01(n)
|
|
Subsidiaries
|
|
Schedule 8.01(s)(i)
|
|
[*****]
|
|
Schedule 8.01(s)(ii)
|
|
[*****]
|
|
Schedule 8.01(u)
|
|
Borrower’s Principal Place of Business and
Chief Executive Office
|
|
Schedule 8.01(v)(ii)
|
|
[*****]
|
|
Schedule 8.01(v)(iii)
|
|
[*****]
|
|
Schedule 8.01(v)(iv)
|
|
[*****]
|
|
Schedule 8.01(v)(vii)
|
|
[*****]
|
|
Schedule 8.01(v)(viii)
|
|
[*****]
|
|
Schedule 8.01(v)(ix)
|
|
[*****]
|
|
Schedule 8.01(v)(x)
|
|
[*****]
|
|
Schedule 8.01(v)(xi)
|
|
[*****]
|
|
Schedule 8.01(w)(i)
|
|
[*****]
|
|
Schedule 8.01(w)(iii)
|
|
[*****]
|
|
Schedule 8.01(w)(v)
|
|
[*****]
|
|
|
|
[*****]
|
|
Schedule 8.01(w)(vi)
|
|
[*****]
|
|
Schedule 8.01(w)(vii)
|
|
[*****]
|
|
Schedule 8.01(w)(viii)
|
|
[*****]
|
|
Schedule 8.01(w)(x)
|
|
[*****]
|
|
Schedule 8.01(w)(xi)
|
|
[*****]
|
|
Schedule 8.01(x)
|
|
[*****]
|
|
Schedule 10.03(a)
|
|
[*****]
|
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
This LOAN AGREEMENT (the
“Amended Agreement”), dated as of August 5, 2008
and amended and restated as of March 18, 2009, is entered into
by and between COWEN HEALTHCARE ROYALTY PARTNERS, L.P., a Delaware
limited partnership (the “ Lender ”), as Lender,
and DYAX CORP., a Delaware corporation, as Borrower. The
Lender and Borrower are hereinafter referred to collectively as the
“ Parties ” or individually as a “
Party .”
W I T N E S S E T
H:
WHEREAS, Borrower is the owner of
the LFRP Intellectual Property (as hereinafter defined) with
respect to the LFRP (as hereinafter defined);
WHEREAS, Borrower has the right to
payments under the License Agreements (as hereinafter
defined);
WHEREAS, on August 5, 2008, the
Parties executed a Loan Agreement (the “ Original Loan
Agreement ”) pursuant to which Borrower borrowed from
Lender an aggregate principal amount of $50,000,000;
WHEREAS, in order to induce the
Lender to enter into the Original Loan Agreement and to extend
credit thereunder, Borrower agreed to grant Lender a security
interest in the LFRP Intellectual Property (as defined in the
Original Loan Agreement);
WHEREAS, Borrower desires to create
a new tranche of Loans in an aggregate principal amount of
$15,000,000;
WHEREAS, in connection with such new
tranche of Loans the Parties desire to amend and restate the
Original Loan Agreement as set forth in this Amended
Agreement;
NOW, THEREFORE, in consideration of
the mutual promises of the Parties, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby
acknowledged, it is mutually agreed by the Parties as
follows:
ARTICLE I
CERTAIN DEFINITIONS
SECTION 1.01.
Definitions . As used herein:
“ Affiliate ”
means any Person that controls, is controlled by, or is under
common control with another Person. For purposes of this
definition, “ control ” shall mean (i) in
the case of corporate entities, direct or indirect ownership of at
least fifty percent (50%) of the stock or shares having the right
to vote for the election of directors, and (ii) in the case of
non-corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the equity interest with the power to direct
the management and policies of such non-corporate
entities.
“ Agent ” means,
(i) if only one Lender is party to this Amended Agreement,
such Lender or (ii) otherwise, Cowen Healthcare Royalty
Partners, L.P. or another Lender reasonably acceptable to
Borrower.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
“ Amended Agreement
” means this Loan Agreement (as amended, restated,
supplemented or otherwise modified from time to time).
“ Applicable Included
Receipts ” means (i) prior to June 30, 2013,
the sum of (a) 75.0% of the first $10.0 million in annual
Included Receipts, (b) 50.0% of annual Included Receipts
greater than $10.0 million and up to and including $15.0 million,
and (c) 25.0% of annual Included Receipts greater than $15.0
million and (ii) after June 30, 2013, 90.0% of all
Included Receipts until the earlier of the Maturity Date or the
complete amortization of the Loans under Section 3.01.
“Applicable Included Receipts” shall exclude FTE
Payments so long as the principal amount of the Loans prepaid
pursuant to Section 3.01(a) exceeds any principal amount
added to the Loans pursuant to Section 4.01(a) (as
calculated on an annual basis for each calendar year) which shall
be determined at the end of any applicable calendar year and shall
be applied to amortization in accordance with Section 3.01(a);
provided that Borrower may, at its option, include such
costs in Applicable Included Receipts on a quarterly basis to pay
scheduled amortization in accordance with
Section 3.01(a).
“ Assignee ” has
the meaning specified in Section 13.01(b).
“ Assignment and
Acceptance ” has the meaning specified in
Section 13.01(c).
“ Borrower ”
means Dyax Corp.
“ Borrower Documents
” means the certificate of incorporation of Borrower
certified by the Delaware Secretary of State and the by-laws of
Borrower (and any similar documentation of any Subsidiary of
Borrower which becomes party to the Loan Documents).
“ Business Day ”
means any day, except a Saturday, Sunday or other day on which
commercial banks in New York are required or authorized by law to
close.
“ Business Report
” means a report in a form agreed upon between the parties
and based on Exhibit A , providing information on
current activities relating to the licensing of the LFRP
Intellectual Property as part of the LFRP.
“ Capital Stock ”
of any Person means any and all shares, interests, ownership
interest units, rights to purchase, warrants, options,
participations or other equivalents of or interests in (however
designated) equity of such Person, including any preferred stock,
but excluding any debt securities convertible into such
equity.
[*****]
“[*****]
Agreement ” means the [*****] Agreement dated [*****]
between [*****] and Borrower.
“[*****] Payments
” means the specified payments that become due and payable to
[*****] pursuant to the [*****] Agreement, as further described in
Schedule 8.01(s)(ii) .
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
2
“ Change of Control
” means:
(i) the acquisition by
any Person or group (within the meaning of Sections
13(d)(3) or 14(d)(2) of the Exchange Act) (other than any
trustee or other fiduciary holding securities under an employee
benefit plan of Borrower or any entity controlled, directly or
indirectly, by Borrower) of beneficial ownership of any capital
stock of Borrower, if after such acquisition, such Person or group
would be the “beneficial owner” (as defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of Borrower representing more than fifty percent (50%)
of the combined voting power of Borrower then outstanding
securities entitled to vote generally in the election of directors;
or
(ii) any transaction
permitted under Section 10.02(a); or
(iii) during any
period of two consecutive years, individuals who at the beginning
of such period constitute the Board of Directors of Borrower
(together with any new directors (other than a director designated
by a Person who has entered into an agreement with Borrower to
effect a transaction described in clause (i) or (ii) of
this definition of “ Change of Control ”), whose
election by such Board of Directors or nomination for election by
Borrower’s shareholders, as applicable, was approved by a
vote of a majority of the directors then still in office who either
were directors at the beginning of such period or whose election or
nomination for election was previously so approved) cease for any
reason to constitute at least a majority of the Board of Directors
of Borrower then in office.
“ Closing Date ”
means August 5, 2008.
“ Code ” means
the Internal Revenue Code of 1986, as amended.
“ Co-Development
Agreement ” means any agreement between Borrower and/or
any of its Subsidiaries and one or more third parties relating to
the discovery, research, development, manufacturing or
commercialization of a product or compound (whether or not derived
from phage display) (i) which would be commonly viewed in the
industry as being a co-development agreement, (ii) under which
Borrower and/or any of its Subsidiaries takes a substantially
different commercial role than under an agreement forming part of
the LFRP and (iii) which has two or more of the following
aspects: (A) shared ownership of product-related
intellectual property or sole ownership of product-related
intellectual property by one party with an exclusive license to the
product-related intellectual property to the other party,
(B) shared management control over product development,
(C) shared financial obligations, and/or (D) shared
commercialization rights to the product. Schedule A
sets forth a complete list of Co-Development Agreements in
existence as of the Tranche B Closing Date.
“ Co-Developed Product
” means any product or compound (whether or not derived from
phage display) which is the subject of a Co-Development Agreement
and in relation to which Borrower has committed on a contingent or
non-contingent basis its own financial re-
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
3
sources and/or has committed non-reimbursed
human resources to discover, research, develop, manufacture or
commercialize such product or compound.
“ Collateral ”
has the meaning specified in the Security Agreement.
“ Company Concentration
Account ” means a segregated account established and
maintained at the Lockbox Bank pursuant to the terms of the Lockbox
Agreement and this Amended Agreement. The Company
Concentration Account shall be the account into which funds in the
Lockbox Account which are payable to Borrower pursuant to this
Amended Agreement are swept in accordance with the terms of this
Amended Agreement.
“ Company LFRP Methods and
Libraries ” shall have the meaning set forth in
Section 8.01(v)(iii).
“ Confidentiality
Agreement ” means that certain confidentiality agreement,
dated
March 3, 2009, between Borrower and Lender.
“ Contract ” has
the meaning specified in Section 8.01(e).
“ Contract Party
” means any party to a License Agreement or In
License.
“ Controlled Affiliate
” with respect to any Person means any Person directly or
indirectly controlling, controlled by or under common control with,
such Person. For the purposes of this Amended Agreement,
“ control ” (including, with correlative
meaning, the terms “ controlling ” and “
controlled ”) means the possession, directly or
indirectly, of the power to direct or cause the direction of the
management and policies of such Person, whether through the
ownership of voting securities, by contract or
otherwise.
“ Default ”
means any condition or event which constitutes an Event of Default
or which, with the giving of notice or the lapse of time or both
would, unless cured or waived, become an Event of
Default.
“ Default Rate ”
means, for any period for which an amount is overdue, a rate per
annum equal for each day in such period to the lesser of
(i) 2% plus the rate otherwise applicable to the Loans as
provided the Section 4.01 and (ii) the maximum rate of
interest permitted under applicable Law.
“ Deficiency Amount
” has the meaning specified in
Section 4.01(a).
“ Discrepancy Notice
” has the meaning specified in
Section 4.02(m).
“ Dispute ” has
the meaning specified in Section 8.01(v)(ix).
“ Disqualified Capital
Stock ” of any Person means any class of Capital Stock of
such Person that, by its terms, or by the terms of any related
agreement or of any security into which it is convertible, puttable
or exchangeable, is, or upon the happening of any event or
the
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
4
passage of time would be, required to be
redeemed by such Person, whether or not at the option of the holder
thereof, or matures or is mandatorily redeemable, pursuant to a
sinking fund obligation or otherwise, in whole or in part, on or
prior to the date which is 91 days after the final maturity date of
the Loans; provided , however , that any class of
Capital Stock of such Person that, by its terms, authorizes such
Person to satisfy in full its obligations with respect to the
payment of dividends or upon maturity, redemption (pursuant to a
sinking fund or otherwise) or repurchase thereof or otherwise by
the delivery of Capital Stock that are not Disqualified Capital
Stock, and that is not convertible, puttable or exchangeable for
Disqualified Capital Stock or Indebtedness, will not be deemed to
be Disqualified Capital Stock so long as such Person satisfies its
obligations with respect thereto solely by the delivery of Capital
Stock that are not Disqualified Capital Stock.
“ Dollars ” or
“ $ ” means lawful money of the United States of
America.
“ ERISA ” means
the Employee Retirement Income Security Act of 1974, as amended,
and the regulations promulgated thereunder.
“ ERISA Affiliate
” at any time means each trade or business (whether or not
incorporated) that would, at any time, be treated, together with
Borrower or any of their respective Subsidiaries, as a single
employer under Title IV or Section 302 of ERISA or
Section 412 of the Code.
“ Event of Default
” has the meaning specified in Section 11.01.
“ Exchange Act ”
means the Securities Exchange Act of 1934 and the regulations
promulgated thereunder.
“ Excluded Agreements
” means Co-Development Agreements, Internally Developed
Product Agreements and Licensed Product Agreements.
Schedule B sets forth a complete list of all Excluded
Agreements in existence as of the Tranche B Closing
Date.
“ Excluded Payments
” means (i) payments under any Excluded Agreement or
(ii) payments relating to or arising out of any activities
relating to the research, development, manufacturing or
commercialization of any Excluded Product.
“ Excluded Product
” means any product or compound (whether or not derived from
phage display) which, at any point, was, is or becomes included in
Borrower’s “pipeline” as an internal product
candidate. An Excluded Product is either an Internally
Developed Product, an In-Licensed Product or a Co-Developed
Product. Schedule B sets forth a complete list
of all Excluded Products in existence as of the Tranche B Closing
Date. Notwithstanding the foregoing, Borrower acknowledges
and agrees that under the terms of certain License Agreements,
Contract Parties and their sublicensees may develop products that
are the same as or similar to Excluded Products and that such same
or similar products shall be not be considered Excluded Products
under this Amended Agreement.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
5
“ Excluded Taxes
” means (i) any Taxes imposed on (or measured by) net
income (including branch profits Taxes) of the Lender, or any
franchise or similar Taxes imposed in lieu thereof, by any
Governmental Authority or taxing authority by the jurisdiction
under the laws of which the Lender is organized or any jurisdiction
in which the Lender is a resident, has an office, conducts business
or has another connection and (ii) in the case of a Foreign
Lender, any withholding tax that is imposed on amounts payable to
such Foreign Lender (a) under law in effect at the time such
Foreign Lender becomes a party to this Amended Agreement (or
designates a new Lending Office), except to the extent that such
Foreign Lender (or its assignor, if any) was entitled, at the time
of designation of a new Lending Office (or assignment), to receive
additional amounts from Borrower with respect to such withholding
tax pursuant to Section 5.01(a) or (b) that is
attributable to such Foreign Lender’s failure to comply with
Section 5.01(b).
“ FDA ” means the
United States Food and Drug Administration.
“ Financial Statements
” means the consolidated balance sheets of Borrower and its
Subsidiaries, audited at December 31, 2006, December 31,
2007 and December 31, 2008 and the related consolidated
statements of operations and comprehensive loss, cash flows and
changes in stockholders’ equity of Borrower and its
Subsidiaries audited for the years ended December 31, 2006,
December 31, 2007 and December 31, 2008, and the
accompanying footnotes thereto, as filed with the SEC, including
the Management’s Discussion and Analysis of Financial
Condition and Results of Operations contained therein.
“ Foreign Lender
” has the meaning specified in
Section 5.01(c).
“ FTE ” means a
full-time equivalent included in FTE Payment costs.
“ FTE Payments ”
means all amounts received from a Contract Party under any License
Agreement in payment for services relating specifically to
Borrower’s and/or any of its Subsidiaries’ costs (or
estimated costs) for the discovery, research and/or development of
peptides, proteins and antibodies as reasonably calculated based on
the subsidization of the full cost of personnel measured in full
time equivalents, other comparable cost-based measures or any
combination of the foregoing. For the avoidance of doubt, FTE
Payments shall not include any technical milestones that relate
specifically to the completion of services, or other related
events.
“ Funded Research
Agreements ” has the meaning specified in the definition
of License Agreement.
“ Future Licenses
” means any License Agreement entered into by Borrower and/or
any of its Subsidiaries after the date hereof with any other
Person, as the same may be amended, supplemented or otherwise
modified from time to time.
“ GAAP ” means
the generally accepted accounting principles in the United States
of America in effect from time to time.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
6
“ Governmental
Authority ” means any nation or government, any state or
other political subdivision thereof, and any entity exercising
executive, legislative, judicial, regulatory or administrative
functions of, or pertaining to, government.
“ Gross Payments
” means all Royalties arising under or payable with respect
to any License Agreement or In License and any collections,
recoveries, payments or other compensation made in lieu thereof and
any amounts paid or payable to Borrower and/or any of its
Subsidiaries in respect of any License Agreement or In License
pursuant to Section 365(n) of the United States
Bankruptcy Code. For the avoidance of doubt, the parties
acknowledge and agree that Gross Payments shall specifically
exclude all Excluded Payments.
“ Guarantee ”
means, as to any Person: (a) any obligation, contingent
or otherwise, of such Person guaranteeing or having the economic
effect of guaranteeing any Indebtedness or other obligation payable
or performable by another Person (the “ primary
obligor ”) in any manner, whether directly or indirectly,
and including any obligation of such Person, direct or indirect
(i) to purchase or pay (or advance or supply funds for the
purchase or payment of) such Indebtedness or other obligation,
(ii) to purchase or lease property, securities or services for
the purpose of assuring the obligee in respect of such Indebtedness
or other obligation of the payment or performance of such
Indebtedness or other obligation, (iii) to maintain working
capital, equity capital or any other financial statement condition
or liquidity or level of income or cash flow of the primary obligor
so as to enable the primary obligor to pay such Indebtedness or
other obligation, or (iv) entered into for the purpose of
assuring in any other manner the obligee in respect of such
Indebtedness or other obligation of the payment or performance
thereof or to protect such obligee against loss in respect thereof
(in whole or in part); or (b) any Lien on any assets of such
Person securing any Indebtedness or other obligation of any other
Person, whether or not such Indebtedness or other obligation is
assumed by such Person.
“ In-Licensed Product
” means any product or compound (whether or not derived from
phage display) in relation to which Borrower expends a substantial
amount of the financial resources to used to discover, research,
and develop or commercialize such product or compound, and to which
Borrower acquired rights to discover, research, develop,
manufacture or commercialize such product or compound
(i) under a Licensed Product Agreement or (ii) under an
option or similar provision expressly included within any License
Agreement where the economic terms applicable to such provision are
consistent with Borrower’s past practices and would be
recognized in the industry as being a bona fide payment for
rights.
“ In Licenses ”
means any existing or future agreement pursuant to which Borrower
and/or any of its Subsidiaries obtains rights to LFRP Intellectual
Property or other rights used in the LFRP.
“ Included Receipts
” means (a) the Gross Payments less (b) [*****]
Payments and Reimbursement Payments, from the first day of the
fiscal quarter of Borrower in which the Closing Date occurs;
provided that for the first fiscal quarter after the Closing
Date the “Included Receipts” were prorated by dividing
such Included Receipts by 90 and multiplying by the number of days
from and including the Closing Date through the end of such
quarter.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
7
“ Indebtedness ”
with respect to any Person means any amount (absolute or
contingent) payable by such Person as debtor, borrower, issuer,
guarantor or otherwise (i) pursuant to an agreement or
instrument involving or evidencing money borrowed, the advance of
credit, a conditional sale or a transfer with recourse or with an
obligation to repurchase, (ii) pursuant to a lease with
substantially the same economic effect as any such agreement or
instrument, (iii) pursuant to any equity interest with a
mandatory obligation to repurchase, (iv) pursuant to
indebtedness of a third party secured by (or for which the holder
of such indebtedness has an existing right, contingent or
otherwise, to be secured by) any Lien on assets owned or acquired
by such Person, whether or not the indebtedness secured thereby has
been assumed, (v) pursuant to an interest rate protection
agreement, foreign currency exchange agreement or other hedging
arrangement, (vi) pursuant to a letter of credit issued for
the account of such Person, or (vii) all Guarantees with
respect to Indebtedness of the types specified in clauses
(i) through (vi) above of another Person. For the
avoidance of doubt, the Indebtedness of any Person shall include
the Indebtedness of any other entity to the extent such Person is
directly liable therefor as a result of such Person’s
ownership interest in or other relationship with such entity,
except to the extent the terms of such Indebtedness provide that
such Person is not liable therefor.
“ Indemnified
Liabilities ” means, collectively, any and all
liabilities, obligations, losses, damages, penalties, claims,
costs, expenses and disbursements of any kind or nature whatsoever
(including the reasonable fees and disbursements of counsel for
Indemnitees in connection with any investigative, administrative or
judicial proceeding commenced or threatened by any Person, whether
or not any such Indemnitee shall be designated as a party or a
potential party thereto, and any fees or expenses actually incurred
by Indemnitees in enforcing the indemnity provided herein), whether
direct, indirect or consequential and whether based on any federal,
state or foreign laws, statutes, rules or regulations
(including securities and commercial laws, statutes, rules or
regulations), on common law or equitable cause or on contract or
otherwise, imposed on, incurred by, or asserted against any such
Indemnitee, in any manner relating to or arising out of this
Amended Agreement or the other Loan Documents or the transactions
contemplated hereby or thereby (including any enforcement of any of
the Loan Documents (including any sale of, collection from, or
other realization upon any of the Collateral).
“ Indemnified Taxes
” has the meaning specified in
Section 5.01(a).
“ Indemnitee ”
has the meaning specified in Section 12.03(a).
“ Independent
Accountants ” has the meaning specified in
4.02(m).
“ Insurance Providers
” has the meaning specified in Section 9.06.
“ Interest Payment Date
” means quarterly on October 15, January 15,
April 15 and July 15 of each year, or if any such day is
not a Business Day, on the next succeeding Business Day, beginning
on October 15, 2008.
“ Interest Rate ”
means (i) with respect to Tranche A Loans, 16.00% per
annum and (ii) with respect to Tranche B Loans, 21.50%
per annum.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
8
“ Internally Developed
Product ” means any product or compound or molecule which
was independently identified by Borrower using its own financial
and/or human resources, the intellectual property to which product
or compound is owned by Borrower and/or any of its
Subsidiaries.
“ Internally Developed
Product Agreement ” means any agreement between Borrower
and/or any of its Subsidiaries and one or more third parties
pursuant to which Borrower and/or any of its Subsidiaries grants a
third party(ies) a license, or an option to obtain a license, to
research, develop and/or commercialize one or more Internally
Developed Products, with or without its phage display technology
and/or library.
“ Knowledge ”
means, with respect to Borrower, as applicable, the knowledge of an
officer or senior manager or other person with similar
responsibility, regardless of title, of Borrower and/or any of its
Subsidiaries relating to a particular matter; provided ,
however , that a person charged with responsibility for the
aspect of the business relevant or related to the matter at issue
shall be deemed to have knowledge of a particular matter if, in the
prudent exercise of his or her duties and responsibilities in the
ordinary course of business, such person should have known of such
matter.
“ Law ” means any
federal, state, local or foreign law, including common law, and any
regulation, rule, requirement, policy, judgment, order, writ,
decree, ruling, award, approval, authorization, consent, license,
waiver, variance, guideline or permit of, or any agreement with,
any Governmental Authority.
“ Lender ” means
the Lender (as defined in the first paragraph hereof) and any
assignee under Section 13.01(b).
“ Lender Bank Account
” means Cowen Healthcare Royalty Partners, L.P.’s
account at JP Morgan Chase Bank, N.A.
“ Lender Concentration
Account ” means a segregated account established for the
benefit of the Lender and maintained at the Lockbox Bank pursuant
to the terms of the Lockbox Agreement and this Amended
Agreement. The Lender Concentration Account shall be the
account into which the funds held in the Lockbox Account which are
payable to the Lender pursuant to this Amended Agreement are swept
in accordance with the terms of this Amended Agreement and the
Lockbox Agreement.
“ Lending Office
” means, with respect to the Lender, its Stamford,
Connecticut office, and with respect to any other Lender, the
office of such Lender designated as its “Lending
Office” in an Assignment and Acceptance, or such other office
as may be otherwise designated in writing from time to time by such
Lender to Borrower.
“ LFRP ” means
the program under which Borrower and any of its Subsidiaries enters
into License Agreements pursuant to which third parties are granted
rights to the LFRP Patents, alone or in combination with LFRP
Technology where the purpose is to generate revenue for Borrower
and/or any of its Subsidiaries by (i) licensing to a third
party rights to use the LFRP
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
9
Patents and/or the LFRP Technology to identify,
isolate, research and/or develop antibodies, peptides and/or
proteins, or (ii) performing research on behalf of third
parties to identify, isolate, research and/or develop antibodies,
peptides and/or proteins.
“ LFRP Intellectual
Property ” means:
(i)
the LFRP Patents and LFRP Technology; and
(ii)
all know-how, materials, trademarks, service marks, trade names and
goodwill associated therewith, trade secrets, data, formulations,
processes, franchises, inventions, software, copyrights, and all
other technology and intellectual property (including biological
materials), and all registrations of any of the foregoing, or
applications therefor, that are (a) owned by, controlled by,
issued to, licensed to, licensed by Borrower and any of its
Subsidiaries and (b) necessary to the performance of the LFRP
as presently conducted by Borrower and any of its Subsidiaries or
as conducted by Borrower and any of its Subsidiaries as of the
Closing Date or during the term of the Loans.
“ LFRP Know-How ”
means any biological material, know-how, data, technical or other
information related to the LFRP Patents and/or LFRP Libraries that
is owned or controlled by Borrower and any of its Subsidiaries as
described in Schedule C hereto, together with all updates
and improvements provided under any Library License Agreements as
of the Closing Date or during the term of the Loans.
“ LFRP Libraries
” means Borrower’s and/or any of its
Subsidiaries’ [*****], Borrower’s and/or any of its
Subsidiaries’ [*****], and Borrower’s and any of its
Subsidiaries’ [*****], all of which are described in
Schedule D hereto, together with all updates and
improvements thereto and any other [*****] that are developed or
obtained by Borrower and any of its Subsidiaries and are
transferred under any Library License Agreement as of the Closing
Date or during the term of the Loans.
“ LFRP Patents
” means the patents and patent applications identified on
Schedule 8.01(v)(ii) and any other patent application
and patent that is: (i) owned by, controlled by, issued
to, licensed to or licensed by Borrower and any of its
Subsidiaries, or for which Borrower and any of its Subsidiaries has
obtained the benefit of a covenant not to sue, as of the Closing
Date or during the term of the Loans necessary to the practice of
[*****]; or (ii) licensed under the LFRP; and any patents
issuing from such applications, together with any reissues,
reexaminations, renewals, and extensions thereof, and all
continuations, continuations-in-part and divisionals of the
applications, in each case throughout the world.
“ LFRP Product ”
means any product owned by one or more third parties that
incorporates an antibody, protein or peptide that was identified
through the use of LFRP Technology and with respect to which
Borrower or any of its Subsidiaries is entitled, under the terms of
a License Agreement or In License, to receive Royalties.
“ LFRP Technology
” means the LFRP Know-How and LFRP Libraries.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
10
“ Liabilities ”
means the liabilities of Borrower excluding deferred
revenue.
“ Library License
Agreements ” has the meaning specified in the definition
of License Agreement.
“ License Agreement
” means any existing or future agreement under which:
(i) Borrower and/or any of its Subsidiaries licenses to a
third party rights to use the technology claimed in the LFRP
Patents to identify, isolate, research and develop antibodies,
peptides and/or proteins (“ Patent License Agreements
”); (ii) Borrower and/or any of its Subsidiaries
licenses to a third party rights to use the LFRP Patents and the
LFRP Technology to identify, isolate, research and develop
antibodies, peptides and/or proteins (“ Library License
Agreements ”); and/or (iii) Borrower and/or any of
its Subsidiaries performs funded research services for third
parties using the LFRP Patents and the LFRP Technology to identify,
isolate, research and develop antibodies, peptides and/or proteins
on behalf of such third parties (“ Funded Research
Agreements ”); in each case as they may be amended,
supplemented or otherwise modified from time to time. License
Agreements shall specifically exclude Excluded Agreements and In
Licenses.
“ Licensed Product
Agreements ” means any product agreement (but excluding
phage or phagemid or protein display technology and/or library
licenses) between Borrower and/or any of its Subsidiaries and one
or more third parties in which Borrower and/or any of its
Subsidiaries acquires the right to develop and commercialize a
product or compound (whether or not derived from phage
display).
“ Lien ” means
any mortgage or deed of trust, pledge, hypothecation, lien, charge,
attachment, set-off, encumbrance or other security interest in the
nature thereof (including any conditional sale agreement, equipment
trust agreement or other title retention agreement, a lease with
substantially the same economic effect as any such agreement or a
transfer or other restriction) or other encumbrance of any nature
whatsoever.
“ Loans ” means
the Tranche A Loan and the Tranche B Loan. References in the
Tranche A Note and the Tranche A Warrant Agreement to
“Loan” shall be deemed to refer to the Tranche A
Loan.
“ Loan Documents
” means this Amended Agreement, the Notes, the Security
Agreement and the Lockbox Agreement.
“ Lockbox Account
” means, collectively, any lockbox and segregated lockbox
account established and maintained at the Lockbox Bank pursuant to
a Lockbox Agreement and this Amended Agreement. The Lockbox
Account shall be the account into which all payments made in
respect of the sale of the LFRP Products are to be remitted and
shall be an escrow account.
“ Lockbox Agreement
” means the agreement entered into by JPMorgan Chase Bank,
N.A., Borrower and Lender, dated as of August 5, 2008 (as the
same may be amended, restated or otherwise modified from time to
time), pursuant to which, among other things, the Lockbox Account,
the Lender Concentration Account and the Company Concentration
Account
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
11
shall be established and maintained and any
agreement with a successor Lockbox Bank entered into in accordance
with Section 4.02(f)(ii).
“ Lockbox Bank ”
means JPMorgan Chase Bank, N.A. or such other bank or financial
institution approved by each of Lender and Borrower.
“ Material Adverse
Effect ” means (i) a material adverse effect on the
business, results of operations, assets or financial condition of
Borrower and its Subsidiaries, taken as a whole, (ii) a
material reduction or other material impairment of the value of the
[*****] or (iv) an impairment of the ability of Borrower
and/or any of its Subsidiaries to perform its obligations under, or
affecting the validity or enforceability of, any Loan Document,
Borrower Document or the Warrant Agreements. The
Parties acknowledge and agree that any delay in, or denial of,
regulatory approval for Dyax’s proprietary kallikrein
inhibitor, known as DX-88, shall not be deemed to constitute a
Material Adverse Effect on the Tranche B Funding Date.
“ Material Licenses
” means those License Agreements set forth on Schedule
8.01(w)(x).
“ Maturity Date ”
means the earlier of (i) the eighth anniversary of the Closing
Date and (ii) the date of any prepayment in full of the
Loan.
“ No-Call Date ”
means August 21, 2012.
“ Notes ” means
the Tranche B Note(s) and the Tranche A Note(s).
“ Notice of Borrowing
” has the meaning specified in Section 2.02.
“ Notices ” has
the meaning specified in Section 13.04.
“ Obligations ”
means, without duplication, the Loans and all present and future
Indebtedness, taxes, liabilities, obligations, covenants, duties,
and debts, owing by Borrower to the Lender, arising under or
pursuant to the Loan Documents, including all principal, interest,
charges, expenses, fees and any other sums chargeable to Borrower
hereunder and under the other Loan Documents (and including any
interest, fees and other charges that would accrue but for the
filing of a bankruptcy action with respect to Borrower, whether or
not such claim is allowed in such bankruptcy action).
“ Original Loan
Agreement ” has the meaning specified in the recitals
hereto.
“ Original Loan
Documents ” means the Loan Documents as such term was
defined under the Original Loan Agreement.
“ Original Security
Agreement ” means the Security Agreement as such term was
defined under the Original Loan Agreement.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
12
“ Original Transaction
Documents ” means the Loan Documents, the Warrant
Agreements, the License Agreements and the Borrower Documents, as
such terms were defined under the Original Loan
Agreement.
“ Participant ”
has the meaning specified in Section 13.02.
“ Party ” and
“ Parties ” have the meanings specified in the
first paragraph hereof.
“ Patent License
Agreements ” has the meaning specified in the definition
of License Agreement.
“ Patent Office ”
means the respective patent office (foreign or domestic) for any
patent.
“ Patriot Act ”
has the meaning specified in Section 13.19.
“ Permitted
Collateralization ” means any asset securitization, sale,
transfer or other disposition by Borrower or any of its
Subsidiaries, individually or when taken together with other
Permitted Collateralizations, generating cash proceeds of $25.0
million or less since the Closing Date which involves in whole or
in part Collateral to the extent simultaneously with the release of
the Collateral in accordance with the Security Agreement Borrower
or any of its Subsidiaries receives cash proceeds no less than the
fair market value thereof, which determination shall be made in
good faith by Borrower’s Board of Directors. Proceeds
of “Permitted Collateralizations” (whether received on
the release thereof or subsequent thereto) shall be applied in
accordance with Section 3.02(c).
“ Permitted Liens
” has the meaning specified in Section 10.03.
“ Person ” means
an individual, corporation, association, limited liability company,
limited liability partnership, partnership, estate, trust,
unincorporated organization or a government or any agency or
political subdivision thereof.
“ Plan ” has the
meaning specified in Section 10.07(a).
“ Plan Assets ”
means assets of any (i) employee benefit plan (as defined in
Section 3(3) of ERISA) subject to Title I of ERISA,
(ii) plan (as defined in Section 4975(e)(1) of the
Code) subject to Section 4975 of the Code or (iii) entity
whose underlying assets include assets of any such employee benefit
plan or plan by reason of the investment by an employee benefit
plan or other plan in such entity.
“ Prepayment Premium
” means with respect to any Loan on any date the Loan (or any
portion thereof) is required to be prepaid pursuant to the proviso
at the end of Section 3.02(b) or any payment made to
amortization prior to the No-Call Date pursuant to
Section 3.02(c), the aggregate amount of all required interest
payments due on the Loan (or the applicable portion) through the
No-Call Date less all interest payments paid in cash through the
date of prepayment.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
13
“ Proceeding ”
has the meaning specified in Section 13.12.
“ Product ” means
the products that are the subject of the License
Agreements.
“ Qualified Capital
Stock ” of any Person means Capital Stock of such Person
other than Disqualified Capital Stock; provided that such
Capital Stock shall not be deemed Qualified Capital Stock to the
extent sold or owed to a Subsidiary of such Person or financed,
directly or indirectly, using funds (i) borrowed from such
Person or any Subsidiary of such Person until and to the extent
such borrowing is repaid or (ii) contributed, extended,
guaranteed or advanced by such Person or any Subsidiary of such
Person (including, without limitation, in respect of any employee
stock ownership or benefit plan). Unless otherwise specified,
Qualified Capital Stock refer to Qualified Capital Stock of
Borrower.
“ Quarterly Report
” means, with respect to the relevant calendar quarter of
Borrower: (i) a report in a form agreed by the parties
and based on Exhibit C showing all payments made by
Borrower and/or any of its Subsidiaries and any Contract Party to
the Lender under this Amended Agreement during such quarter, such
report showing in detail the basis for the calculation of such
payments and exclusions; (ii) a reconciliation of such report
referred to in clause (i) above to all information and data
deliverable to Borrower and/or any of its Subsidiaries by the
Contract Parties to any License Agreements, together with relevant
supporting documentation, as well as a reconciliation with the
consolidated total revenues of Borrower prepared in accordance with
GAAP; and (iii) such additional information as the Lender may
reasonably request.
“ Register ” has
the meaning set up in Section 5.07.
“ Regulatory Agency
” means a Governmental Authority with responsibility for the
regulation of the research, development, marketing or sale of drugs
or pharmaceuticals in any jurisdiction, including the FDA, the U.S.
National Institutes of Health and the EMEA.
“ Reimbursement
Payments ” means all amounts received from a Contract
Party under any Funded Research Agreements in reimbursement on a
pure pass-through basis for out-of-pocket costs incurred and
invoiced by Borrower and/or any of its Subsidiaries (other than FTE
Payments) in connection with the provision of services relating to
the identifying, isolating, and researching antibodies, peptides
and or proteins.
“ Restricted Payment
” means any of the following:
(i) the declaration or payment of
any dividend or any other distribution on Capital Stock of Borrower
or any Subsidiary or any payment made to the direct or indirect
holders (in their capacities as such) of Capital Stock of Borrower
or any Subsidiary, including, without limitation, any payment in
connection with any merger or consolidation involving Borrower but
excluding (a) dividends or distributions payable solely in
Qualified Capital Stock or through accretion or accumulation of
such dividends on such Capital Stock and (b) in the case of
Subsidiaries, dividends or distributions payable to Borrower or to
a Subsidiary and pro rata dividends or distributions payable to
minority stockholders of any Subsidiary; or
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
14
(ii)
the redemption of any Capital Stock of Borrower or any Subsidiary,
including, without limitation, any payment in connection with any
merger or consolidation involving Borrower but excluding any such
Capital Stock held by Borrower or any Subsidiary.
“ Royalties ”
means the gross amount of all royalties, minimum royalty payments,
profit payments, license fees, settlement payments, judgments,
payments, securities, consideration or any other remuneration of
any kind payable or received under any License Agreement or any In
License (but in the case of an In License only to the extent such
royalties, payments and fees relate to the LFRP) and all accounts
(as such term is defined in the New York Uniform Commercial Code)
evidencing or giving rise to any of the foregoing.
“ SEC ” has the
meaning set forth in Section 8.01(d).
“ Security Agreement
” means the Amended and Restated Security Agreement, dated
the Tranche B Closing Date, substantially in the form of
Exhibit D hereto, between the Lender and Borrower
securing the Obligations of Borrower hereunder as supplemented by
any amendments or joinders thereto.
“ Significant
Subsidiary ” means any Subsidiary of Borrower which would
constitute a “significant subsidiary” as defined in
Rule 1.02 of Regulation S-X under the Securities Act of
1933, as amended and the Securities Exchange Act of 1934, as
amended.
“ Subsidiary ”
means, with respect to any Person, at any time, any entity of which
more than fifty percent (50%) of the outstanding Voting Stock or
other equity interest entitled ordinarily to vote in the election
of the directors or other governing body (however designated) is at
the time beneficially owned or controlled directly or indirectly by
such Person, by one or more such entities or by such Person and one
or more such entities.
“ Surviving Person
” means, with respect to any Person involved in or that makes
any disposition, the Person formed by or surviving such disposition
or the Person to which such disposition is made.
“ Taxes ” has the
meaning specified in Section 5.01(a).
“ Tranche ”
means, with respect to any Loan, whether such Loan is a Tranche A
Loan or a Tranche B Loan.
“ Tranche A Aggregate
Accrual ” has the meaning specified in
Section 4.01(d).
“ Tranche A Deficiency
Amount ” has the meaning specified in
Section 4.01(a).
“ Tranche A Loan
” means the Tranche A Loan made by the Lender on the Closing
Date pursuant to Section 2.01 of the Original Loan
Agreement.
“ Tranche A Loan
Percentage ” means [*****]
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
15
“ Tranche A Maximum
Accrual ” has the meaning specified in
Section 4.01(d).
“ Tranche A Note
” means the note issued by Borrower to Lender evidencing the
Tranche A Loans made on the Closing Date to Borrower and any
replacement(s) thereof issued in accordance with
Section 13.10.
“ Tranche A Warrant
” has the meaning ascribed to “Warrant” in the
Tranche A Warrant Agreement.
“ Tranche A Warrant
Agreement ” means the Warrant Agreement between Borrower
and Lender dated the Closing Date.
“ Tranche B Aggregate
Accrual ” has the meaning specified in
Section 4.01(e).
“ Tranche B Commitment
” means $15,000,000.
“ Tranche B Closing
Date ” means March 18, 2009.
“ Tranche B Deficiency
Amount ” has the meaning specified in
Section 4.01(a).
“ Tranche B Funding
Date ” means the date on which the Lender makes the
Tranche B Loan, which Tranche B Loan shall be made on or before
March 31, 2009.
“ Tranche B Loan
” means the Tranche B Loan to be made by the Lender pursuant
to Section 2.02 of this Amended Agreement.
“ Tranche B Loan
Percentage ” means [*****]
“ Tranche B Maximum
Accrual ” has the meaning specified in
Section 4.01(e).
“ Tranche B Note
” means a promissory note, substantially in the form set
forth in Exhibit B , in the amount of the Tranche B
Loan, evidencing such Tranche B Loan.
“ Tranche B Warrant
” has the meaning ascribed to “Warrant” in the
Tranche B Warrant Agreement.
“ Tranche B Warrant
Agreement ” means the Warrant Agreement between Borrower
and Lender substantially in the form attached hereto as
Exhibit K .
“ Transaction Documents
” means the Loan Documents, the Warrant Agreements, the
License Agreements and the Borrower Documents.
“ U.S .” means
the United States of America.
“ Voting Stock ”
means Capital Stock issued by a company, or equivalent interests in
any other Person, the holders of which are ordinarily, in the
absence of contingencies, entitled
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
16
to vote for the election of directors (or
persons performing similar functions) of such Person, even if the
right so to vote has been suspended by the happening of such
contingency.
“ Warrant Agreements
” means the Tranche A Warrant Agreement and the Tranche B
Warrant Agreement.
“ Webphage
® Software ” means Borrower’s analysis and data
storage software for [*****] screening as embodied in the United
States copyright registration No. TX 5989121 issued
May 14, 2004, and any updates, improvements or modifications
thereto (in human readable, source code and object code
forms).
“ Wholly Owned
Subsidiary ” means, as to any person, (a) any
corporation 100% of whose capital stock (other than
directors’ qualifying shares) is at the time owned by such
person and/or one or more Wholly Owned Subsidiaries of such person
and (b) any partnership, association, joint venture, limited
liability company or other entity in which such person and/or one
or more Wholly Owned Subsidiaries of such person have a 100% equity
interest at such time.
SECTION 1.02.
Interpretation; Headings . Each term used in any
Exhibit to this Amended Agreement and defined in this Amended
Agreement but not defined therein shall have the meaning set forth
in this Amended Agreement. Unless the context otherwise
requires, (a) “including” means “including,
without limitation” and (b) words in the singular
include the plural and words in the plural include the
singular. A reference to any party to this Amended Agreement,
any other Transaction Document or any other agreement or document
shall include such party’s successors and permitted
assigns. A reference to any agreement or order shall include
any amendment of such agreement or order from time to time in
accordance with the terms herewith and therewith. A reference
to any legislation, to any provision of any legislation or to any
regulation issued thereunder shall include any amendment thereto,
any modification or re-enactment thereof, any legislative provision
or regulation substituted therefore and all regulations and
statutory instruments issued thereunder or pursuant thereto.
Unless otherwise indicated, all references to the Original Credit
Agreement in any Loan Document or other document or instrument
delivered in connection therewith shall be deemed to refer to this
Amended Agreement and the provisions hereof. The headings
contained in this Amended Agreement are for convenience and
reference only and do not form a part of this Amended
Agreement. Section, Article and Exhibit references
in this Amended Agreement refer to sections or articles of, or
exhibits to, this Amended Agreement unless otherwise
specified. Borrower acknowledges and agrees that it was
represented by counsel in connection with the execution and
delivery of the Loan Documents to which it is a party, that it and
its counsel reviewed and participated in the preparation and
negotiation hereof and thereof and that any rule of
construction to the effect that ambiguities are to be resolved
against the drafting party shall not be employed in the
interpretation hereof or thereof.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
17
ARTICLE II
COMMITMENT; DISBURSEMENT; FEES
SECTION 2.01.
Commitment to Lend . On the terms set forth herein,
the Lender shall, on the Tranche B Funding Date, make a loan
hereunder to Borrower in a principal amount equal to the
Tranche B Commitment.
SECTION 2.02.
Notice of Borrowing . Subject to Section 2.01,
Borrower shall, simultaneous with the execution of this Amended
Agreement, give the Lender notice, substantially in the form set
forth in Exhibit E (the “ Notice of
Borrowing ”) that Borrower wishes to borrow a principal
amount equal to the Tranche B Commitment on the Tranche B
Funding Date. The Tranche B Commitment shall
automatically terminate upon funding of the Tranche B Loan on
the Tranche B Funding Date.
SECTION 2.03.
Disbursement . On the terms set forth herein, the
Lender shall, on the Tranche B Funding Date, credit, in same day
funds, an amount equal to the Tranche B Commitment to the account
of Borrower which Borrower shall have designated for such purpose
in the Notice of Borrowing less the initial expenses referred to in
Section 4.04 for which invoices have been received by
Borrower.
SECTION 2.04.
Commitment Not Revolving . The Lender’s
commitment to lend hereunder is not revolving in nature, and any
amount of the Loans repaid or prepaid may not be
reborrowed.
ARTICLE III
REPAYMENT
SECTION 3.01.
Amortization .
(a)
On each Interest Payment Date (except as otherwise expressly
provided herein), Borrower shall (A) repay the portion of the
outstanding principal amount of the Tranche A Loans at par which is
equal to the product of (i) the difference between
(x) Applicable Included Receipts for the prior fiscal quarter
less (y) any portion of such Applicable Included Receipts used
to pay cash interest on the Loans pursuant to Section 4.01(a),
(ii) multiplied by the Tranche A Loan Percentage and
(B) repay the portion of the outstanding principal amount of
the Tranche B Loans at par which is equal to the product of
(i) the difference between (w) Applicable Included
Receipts for the prior fiscal quarter less (z) any portion of
such Applicable Included Receipts used to pay cash interest on the
Loans pursuant to Section 4.01(a), (ii) multiplied by the
Tranche B Loan Percentage.
(b)
The balance of the outstanding principal amount of the Loans,
together with any accrued and unpaid interest, shall be due and
payable in cash on the Maturity Date.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
18
SECTION 3.02.
Optional Prepayment; Mandatory Prepayment .
(a)
Borrower may, subject to Section 12.01, prepay the Loans in
whole or in part, together with accrued and unpaid interest on the
amount prepaid at any time after the No-Call Date; provided
that (i) the outstanding principal balance of the Loans after
giving effect to a voluntary partial prepayment shall be not less
than [*****], (ii) each prepayment shall be in an amount that
is an integral multiple of [*****] and not less than [*****] or, if
less, the outstanding principal amount of the applicable Tranche of
the Loans and (iii) Borrower shall not be permitted to prepay
the Tranche B Loans until all payments of principal and any other
amounts owing to the Lender in respect of the Tranche A Loans have
been paid in full in cash. If Borrower wishes to make such a
prepayment, it shall give the Lender Notice to that effect not
later than the 30th day before the date of the prepayment,
specifying the date on which the prepayment is to be made and the
amount to be prepaid. Such Notice shall constitute
Borrower’s irrevocable commitment to prepay that amount on
that date, together with interest accrued on the amount prepaid to
but excluding the prepayment date.
(b)
If a Change of Control or any transaction permitted by
Section 10.02(a) hereof occurs then, at the option of the
Lender, any or all of the Loans as requested by the Lender to be
prepaid (including all accrued and unpaid interest) shall be due
and payable hereunder, to the extent permitted by law, and shall be
deemed part of the amounts due and payable hereunder subject to
acceleration (either declared or immediate as provided in
Section 11.02); provided that if the Change of Control
or any transaction permitted by Section 10.02(a) hereof
occurs prior to the No-Call Date, then such prepayment shall be
accompanied by the Prepayment Premium with respect to that portion
of the Loans requested by the Lender to be so prepaid. The
Prepayment Premium in respect of the Tranche A Loans shall be paid
prior to any Prepayment Premium with respect to the Tranche B
Loans.
(c)
With respect to Permitted Collateralizations, Borrower shall apply
(or cause to be applied): (A) [*****] of all proceeds of
Permitted Collateralizations (the “ Sweep Proceeds
”) to amortize (i) principal (including all accrued and
unpaid interest in respect thereof) on the Tranche A Loans equal to
the Sweep Proceeds multiplied by the Tranche A Loan Percentage and
(ii) principal (including all accrued and unpaid interest in
respect thereof) on the Tranche B Loans equal to the Sweep Proceeds
multiplied by the Tranche B Loan Percentage, in each case, by
making a cash payment to the Lender which cash payment shall also
include the Prepayment Premium in respect of such amortized amount
if such Permitted Collateralization is consummated prior to the
No-Call Date (which Prepayment Premium shall not affect the
principal or interest on the Loan) and (B) [*****] of the cash
proceeds shall be paid to the Lenders (without affecting the
principal or interest payable on any Loan). The Prepayment
Premium in respect of the Tranche A Loans shall be paid prior to
any Prepayment Premium with respect to the Tranche B
Loans.
SECTION 3.03.
Illegality . If the Lender determines at any time that
any Law or treaty or any change therein or in the interpretation or
application thereof makes or will make it unlawful for the Lender
to fulfill its commitment in accordance with Section 2.01, to
maintain the Loans (including additional amounts pursuant to
Section 4.01(a)) or to claim or receive any
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
19
amount payable to it hereunder, the Lender shall
give Notice of that determination to Borrower, whereupon the
obligations of the Lender hereunder shall terminate. If any
such Notice is given after the disbursement of the Loans, Borrower
shall prepay the Loans in full on the Interest Payment Date
following the date the Notice is given; provided ,
however , that if the Lender certifies to Borrower that
earlier prepayment is necessary in order to enable the Lender to
comply with the relevant Law, treaty or change and specifies an
earlier date for the prepayment, Borrower shall make the prepayment
on the date so specified. Prepayment pursuant to this
Section 3.03 shall be made together with interest accrued and
unpaid on the Loans to the date of prepayment and all other amounts
then payable to the Lender hereunder. Each Notice delivered
pursuant to this Section 3.03 shall be effective when
sent.
ARTICLE IV
INTEREST; EXPENSES
SECTION 4.01.
Interest Rate .
(a)
Except as otherwise expressly provided in Section 4.03,
(i) the Tranche A Loans shall bear interest at a rate per
annum equal to 16.00% and the Tranche B Loans shall bear interest
at a rate per annum equal to 21.50% and, in each case, shall be
paid in cash as provided in Section 4.01(c); provided
that Borrower shall be required to pay interest in cash only to the
extent of the Applicable Included Receipts for the immediately
preceding fiscal quarter and shall apply such cash to the interest
on the Tranche A Loans prior to making interest payments on the
Tranche B Loans. If Borrower is unable to pay the cash
interest payments required under the first sentence of this
Section 4.01(a) out of Applicable Included Receipts or
otherwise pursuant to the last sentence of this
Section 4.01(a) because (i) the then Applicable
Included Receipts are less than 16.00% per annum, paid quarterly,
of the principal amount of the Tranche A Loans (such deficiency,
the “ Tranche A Deficiency Amount ”) or
(ii) the difference between (A) the then Applicable
Included Receipts and (B) the cash payments made in respect of
accrued interest on the Tranche A Loans on such Interest Payment
Date, is less than 21.50% per annum, paid quarterly, of the
principal amount of the Tranche B Loans (such deficiency, the
“ Tranche B Deficiency Amount ” and, each of
(x) the Tranche B Deficiency Amount and (y) the Tranche A
Deficiency Amount, a “ Deficiency Amount ”),
then, in each case, any Deficiency Amount shall be paid in kind, on
a quarterly basis, and on each such date, the Lender shall be
deemed to have made an additional term loan of the applicable
Tranche in a principal amount equal to the aggregate amount of
interest so paid on its outstanding Loans. Each such Loan
shall (A) be deemed to be a Loan for all purposes under this
Amended Agreement and (B) accrue interest in accordance with
this Section 4.01. Borrower shall deliver to each Lender
all original issue discount information relating to the Loans as
may be required by applicable law. Notwithstanding any other
provision herein, Borrower may, at its option, pay all or any
portion of any Deficiency Amount when due out of other funds held
by Borrower.
(b)
All interest hereunder shall be computed on the basis of a 360-day
year of twelve 30-day months.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
20
(c)
Accrued interest on each Loan shall be payable to the Lender at the
Lockbox Account or as otherwise notified to Borrower in arrears on
each Interest Payment Date for such Loan; provided that
(i) interest accrued pursuant to Section 4.04 shall be
payable on demand, in the same form as interest payable on the next
Interest Payment Date, and (ii) in the event of any repayment
or prepayment of any Loan, accrued interest on the principal amount
repaid or prepaid shall be payable on the date of such repayment or
prepayment.
(d)
On each Interest Payment Date commencing with the first Interest
Payment Date following the fifth (5th) anniversary of the Closing
Date, if the aggregate amount that would be includible in income
with respect to the Tranche A Note for periods ending on or before
such Interest Payment Date (within the meaning of
Section 163(i) of the Code) (the “ Tranche A
Aggregate Accrual ”) would exceed an amount equal to the
sum of (i) the aggregate amount of interest to be paid (within
the meaning of Section 163(i) of the Code) under the
Tranche A Note on or before such Interest Payment Date (determined
without regard to the amounts payable on such Interest Payment Date
under this Section 4.01(d)), and (ii) the product of
(A) the issue price (as defined in Sections 1273(b) and
1274(a) of the Code) of the Tranche A Note and (B) the
yield to maturity (interpreted in accordance with
Section 163(i) of the Code) of the Tranche A Note (such
sum, the “ Tranche A Maximum Accrual ”), then
Borrower shall pay to the Lender in cash an amount equal to the
excess, if any, of the Tranche A Aggregate Accrual over the Tranche
A Maximum Accrual, and the amount of such payment shall be treated
for any period ending after such Interest Payment Date as an amount
of interest to be paid (within the meaning of
Section 163(i) of the Code) under the Tranche A
Note.
(e)
On each Interest Payment Date commencing with the first Interest
Payment Date following the fifth (5th) anniversary of the Tranche B
Funding Date, if the aggregate amount that would be includible in
income with respect to the Tranche B Note for periods ending on or
before such Interest Payment Date (within the meaning of
Section 163(i) of the Code) (the “ Tranche B
Aggregate Accrual ”) would exceed an amount equal to the
sum of (i) the aggregate amount of interest to be paid (within
the meaning of Section 163(i) of the Code) under the
Tranche B Note on or before such Interest Payment Date (determined
without regard to the amounts payable on such Interest Payment Date
under this Section 4.01(e)), and (ii) the product of
(A) the issue price (as defined in Sections 1273(b) and
1274(a) of the Code) of the Tranche B Note and (B) the
yield to maturity (interpreted in accordance with
Section 163(i) of the Code) of the Tranche B Note (such
sum, the “ Tranche B Maximum Accrual ”), then
Borrower shall pay to the Lender in cash an amount equal to the
excess, if any, of the Tranche B Aggregate Accrual over the Tranche
B Maximum Accrual, and the amount of such payment shall be treated
for any period ending after such Interest Payment Date as an amount
of interest to be paid (within the meaning of
Section 163(i) of the Code) under the Tranche B
Note.
SECTION 4.02.
Lockbox Account .
(a)
On the Closing Date, the Parties entered into the Lockbox Agreement
with the Lockbox Bank.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
21
(b)
The Lender Concentration Account shall be held solely for the
benefit of the Lender, subject to the terms and conditions of this
Amended Agreement. The Lender shall have immediate and full
access to any funds held in the Lender Concentration Account and
such funds shall not be subject to any conditions or restrictions
whatsoever. The Company Concentration Account shall be held
solely for the benefit of Borrower, subject to the terms and
conditions of this Amended Agreement, the Security Agreement and
the other Transaction Documents. Subject to the terms and
conditions of this Amended Agreement, the Security Agreement and
the other Transaction Documents, Borrower shall have immediate and
full access to any funds held in the Company Concentration Account
and such funds shall not be subject to any conditions or
restrictions whatsoever other than those of the Lockbox Bank;
provided , however , that nothing herein shall
(i) affect or reduce Borrower’s obligations to pay in
full all amounts due to the Lender under this Amended Agreement, or
(ii) in any manner limit the recourse of the Lender to the
assets of Borrower to satisfy Borrower’s
obligations.
(c)
Sweeps from the Lockbox Account shall be made pursuant to
Exhibit F .
(d)
Borrower shall pay for all fees, expenses and charges of the
Lockbox Bank by debiting the Company Concentration
Account.
(e)
With respect to any License Agreement, In License or invoice
entered into or issued by Borrower in relation thereto, Borrower
shall immediately (A) notify the applicable Contract Party to
remit to the Lockbox Account when due all Royalties that are due
and payable to Borrower in respect of or derived from such License
Agreement, In License or invoice and (B) in each case, provide
to the Lender a copy of each such notification.
(f)
Borrower shall have no right to terminate the Lockbox Account
without Lender’s prior written consent. Any such
consent, which the Lender may grant or withhold in its discretion,
shall be subject to the satisfaction of each of the following
conditions to the satisfaction of the Lender:
(i)
the successor Lockbox Bank shall be acceptable to the
Lender;
(ii)
Lender, Borrower and the successor Lockbox Bank shall have entered
into a lockbox agreement substantially in the form of the Lockbox
Agreement initially entered into and such agreement shall be
considered the “Lockbox Agreement” under this Amended
Agreement and the other Loan Documents;
(iii)
all funds and items in the accounts subject to the Lockbox
Agreement to be terminated shall be transferred to the new accounts
held at the successor Lockbox Bank prior to the termination of the
then existing Lockbox Bank; and
(iv)
Borrower shall have received evidence that all of the applicable
parties paying Royalties have been instructed to remit all future
payments to the new accounts held at the successor Lockbox
Bank.
(g)
[Intentionally Omitted]
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
22
(h)
All Gross Payments shall be paid into the Lockbox Account or to any
other account(s) designated in writing by the
Lender(s) to Borrower, and amounts deposited therein shall be
treated as described in Exhibit F .
(i)
Borrower shall pay voluntary prepayments made at the election of
Borrower in accordance with Section 3.02(a) or any
payment made in accordance with the last sentence of
Section 4.01(a) to the Lockbox Account.
(j)
In the event any party to a License Agreement including any party
to a Future License remits any Royalties directly to Borrower or
otherwise except to the Lockbox Account, Borrower shall immediately
(i) remit any such Royalties to the Lockbox Account (or, if
for some reason such account is no longer in effect or payment
cannot be made into such account, Borrower shall remit such
Royalties by wire transfer of immediately available funds directly
to Lender Bank Account), (ii) notify such party to remit any
future Royalties to the Lockbox Account and (iii) provide to
Lender a copy of such notice.
(k)
Amounts payable pursuant to this Section 4.02 shall be in
addition to any amounts payable under Section 4.02(d) of
this Amended Agreement.
(l)
Any payments, other than from funds paid to Lender from the Lender
Concentration Account, to be made by Borrower to Lender hereunder
or under any other Transaction Document shall be made by wire
transfer of immediately available funds to Lender Bank
Account.
(m)
Within [*****] following delivery to Lender by Borrower of the
Quarterly Report for the fourth fiscal quarter of each calendar
year during the term of the Loans, to the extent that either Lender
or Borrower has determined that there is a discrepancy as to the
amounts paid to Lender hereunder for such calendar year, then the
Person who has made such determination may notify the other in
writing of such discrepancy indicating in reasonable detail its
reasons for such determination (the “ Discrepancy
Notice ”). In the event that either Agent or
Borrower delivers to the other party a Discrepancy Notice, Lenders
and Borrower shall meet in person or by telephone conference as
specified by Lender within [*****] (or such other time as mutually
agreed by the parties) after the receiving party has received a
Discrepancy Notice to resolve in good faith such
discrepancy.
If the
discrepancy has been resolved and, as a result thereof, it is
determined that a payment is owing by Lender to Borrower or by
Borrower to Lender, then the Party owing such payment shall
promptly pay such payment to the other Party. If, within
[*****] after receipt of the Discrepancy Notice, Borrower and
Lender cannot resolve any such discrepancies, then Lender and
Borrower shall promptly instruct their respective firms of
independent certified public accountants to select, within [*****]
thereafter, a third internationally recognized accounting firm (the
“ Independent Accountants ”). After
offering Borrower and its representatives and Lender and their
representatives the opportunity to present their positions as to
the disputed items, which opportunity shall not extend for more
than [*****] after the Independent Accountants have been selected,
the Independent Accountants shall review the disputed matters and
the
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
23
materials submitted by Borrower and Lender and,
as promptly as practicable, deliver to Borrower and Lender a
statement in writing setting forth its determination of the proper
treatment of the discrepancies as to which there was disagreement,
and that determination will be final and binding upon the Parties
without any further right of appeal. If Borrower has
delivered the Discrepancy Notice that has resulted in the selection
of the Independent Accountants, Borrower will bear all the charges
of the Independent Accountants. If Agent has delivered the
Discrepancy Notice that has resulted in the selection of the
Independent Accountants, Lenders will bear all the charges of the
Independent Accountants unless the Independent Accountants
determine that the amounts paid to Lender for the applicable
calendar year underpaid Lender by an amount equal or in excess of
[*****] of the amounts determined to be due to Lender for such
calendar year, in which event Borrower shall bear all of the
charges of the Independent Accountants.
SECTION 4.03.
Interest on Late Payments . If any amount payable by
Borrower to the Lender hereunder is not paid when due (whether at
stated maturity, by acceleration or otherwise), interest shall
accrue on any such unpaid amounts, both before and after judgment
during the period from and including the applicable due date, to
but excluding the day the overdue amount is paid in full, at a rate
per annum equal to the Default Rate. Interest accruing under
this Section 4.03 shall be payable from time to time on demand
of the Lender.
SECTION 4.04.
Initial Expenses . Borrower shall reimburse the
Lender, on the Tranche B Closing Date as provided in
Section 2.03, for all (a) actual, documented
out-of-pocket fees and expenses incurred by the Lender (including
all fees and expenses of outside counsel to the Lender), supported
by reasonable documentation, in connection with the negotiation,
preparation, execution and delivery of this Amended Agreement and
the other Transaction Documents including any amendment or waiver
with respect thereto and (b) reasonable fees and expenses,
supported by reasonable documentation, of due diligence conducted
by the Lender or other parties (including outside counsel to the
Lender) at the request of the Lender; provided that Borrower
shall not be required to reimburse any amounts pursuant to this
Section 4.04 in excess of [*****] in the aggregate.
SECTION 4.05.
Administration and Enforcement Expenses . Borrower
shall promptly reimburse the Lender on demand for all reasonable
costs and expenses incurred by the Lender (including the reasonable
fees and expenses of one outside counsel to the Lenders) as a
consequence of or in connection with any Default or Event of
Default.
ARTICLE V
TAXES
SECTION 5.01.
Taxes .
(a)
Except as otherwise required by Law, any and all payments by
Borrower under this Amended Agreement or the Notes (including
payments with respect to the Loans) shall be made free and clear of
and without deduction for any and all present and future taxes,
levies, duties, imposts, deductions, charges, fees or withholdings,
and all interest, penalties and other liabilities with respect
thereto (collectively, “ Taxes ”) imposed by any
Governmental Authority
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
24
or taxing authority in any jurisdiction.
If any Taxes other than Excluded Taxes (“ Indemnified
Taxes ”) shall be required by Law to be deducted from or
in respect of any sum payable under this Amended Agreement or the
Notes to a Lender, (i) the sum payable by Borrower shall be
increased as may be necessary so that after making all required
deductions of Indemnified Taxes the Lender shall receive an amount
equal to the sum it would have received had no such deductions been
made and (ii) Borrower shall make such deductions and pay the
full amount deducted to the relevant Governmental Authority or
taxing authority in accordance with applicable Law.
(b)
Any Lender claiming additional amounts payable pursuant to
Section 5.01(a) shall use its reasonable efforts
(consistent with its internal policies and applicable Law) to
change the jurisdiction of its lending office if such a change
would reduce any such additional amounts (or any similar amount
that may thereafter accrue) and would not, in the sole discretion
of such Lender, be otherwise disadvantageous to such
Lender.
(c)
If a Lender is not a “United States person” within the
meaning of Section 7701(a)(30) of the Code (a “
Foreign Lender ”), then such Foreign Lender shall
provide to Borrower (i) in the case of a Foreign Lender
claiming exemption from U.S. federal withholding tax under
Section 871(h) or 881(c) of the Code with respect to
payments of “portfolio interest,” (x) two accurate
and complete original signed copies of IRS Form W-8BEN (or a
successor form) properly completed and duly executed by such
Foreign Lender and (y) a certificate to the effect that such
Foreign Lender is not (A) a “bank” within the
meaning of Section 881(c)(3)(A) of the Code, (B) a
“10 percent shareholder” of Borrower within the meaning
of Section 881(c)(3)(B) of the Code or (C) a
“controlled foreign corporation” described in
Section 881(c)(3)(C) of the Code, (ii) if the
payments receivable by the Foreign Lender are effectively connected
with the conduct of a trade or business in the United States, two
accurate and complete original signed copies of IRS
Form W-8ECI (or a successor form), (iii) in the case of a
Foreign Lender that is entitled to benefits under an income tax
treaty to which the United States is a party that reduces the rate
of withholding tax on payments of interest, two accurate and
complete original signed copies of IRS Form W-8BEN (or a
successor form) indicating that such Foreign Lender is entitled to
receive payments under this Amended Agreement and the Notes with
reduced or no deduction of any United States federal income
withholding tax or (iv) in the case of a Foreign Lender acting
as an intermediary, two accurate and complete original signed
copies of IRS Form W-8IMY (or a successor form). Such
forms shall be delivered by such Foreign Lender on or prior to the
date that it becomes a Lender under this Amended Agreement, at any
time thereafter when a change in the Foreign Lender’s
circumstances renders an existing form obsolete or invalid or
requires a new form to be provided, and within fifteen Business
Days after a reasonable written request of Borrower from time to
time thereafter. Notwithstanding any other provision of this
Section 5.01(c), no Foreign Lender shall be required to
deliver any form pursuant to this Section 5.01(c) that
such Foreign Lender is not legally able to deliver.
(d)
Each Lender that is not a Foreign Lender shall provide two properly
completed and duly executed copies of Form W-9 (or successor
form) at the times specified for delivery of forms under
Section 5.01(c).
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
25
(e)
Each Lender having assigned its rights and obligations hereunder in
whole or in part or having granted a participating interest in its
Loans shall collect from such assignee or participant the documents
described in Sections 5.01(c) and (d) as
applicable.
(f)
The Lender shall not file any IRS form under
Section 6050P of the Code reporting any cancellation of
indebtedness income of the Borrower as a result of the transactions
contemplated by this Amended Agreement and the other
Transaction Documents.
SECTION 5.02.
Receipt of Payment . Within thirty days after the date
of any payment of Taxes withheld by Borrower in respect of any
payment to the Lender, Borrower shall furnish to the Lender the
original or a certified copy of a receipt evidencing payment
thereof or other evidence reasonably satisfactory to the
Lender.
SECTION 5.03.
Other Taxes . Borrower shall promptly pay any
registration or transfer taxes, stamp duties or similar levies, and
any penalties or interest that may be due with respect thereto,
that may be imposed in connection with the execution, delivery,
registration or enforcement of this Amended Agreement, the Notes
issued hereunder or any other Transaction Document or the filing,
registration, recording or perfecting of any security interest
contemplated by this Amended Agreement.
SECTION 5.04.
Indemnification . If the Lender pays any Taxes that
Borrower is required to pay pursuant to this Article V,
Borrower shall indemnify the Lender on demand in full in the
currency in which such Taxes are paid, whether or not such Taxes
were correctly or legally asserted, together with interest thereon
from and including the date of payment to, but excluding, the date
of reimbursement at the Default Rate. The Lender shall
promptly notify Borrower if any claim is made against the Lender
for any Taxes for which Borrower would be responsible to indemnify
the Lender pursuant to this Section 5.04.
SECTION 5.05.
Loans Treated As Indebtedness . The Parties agree to
treat the Loans as indebtedness for borrowed money of Borrower for
all tax purposes. The Parties agree not to take any position
that is inconsistent with the provisions of this Section 5.05
on any tax return or in any audit or other administrative or
judicial proceeding unless (i) the other Party has consented
to such actions, or (ii) the Party that contemplates taking
such an inconsistent position has been advised by nationally
recognized tax counsel in writing that it is more likely than not
that (x) there is no “reasonable basis” (within
the meaning of Treasury Regulation Section 1.6662-3(b)(3)) for
the position specified in this Section 5.05 or (y) taking
such a position would otherwise subject the Party to penalties
under the Code.
SECTION 5.06.
Allocation of Issue Price . The Tranche A Note
and the Tranche A Warrant, taken together, constitute an
“investment unit” for purposes of
Section 1273(c)(2) of the Code. In accordance with
Sections 1273(c)(2)(A) and 1273(b)(2) of the Code, the
issue price of the investment unit is the purchase price of the
Tranche A Note, with $431,761 thereof representing the fair
market value of the Tranche A Warrant. The Tranche B
Note and the Tranche B Warrant, taken together, constitute an
“investment unit” for purposes of
Section 1273(c)(2) of the Code. In accordance with
Sections 1273(c)(2)(A) and 1273(b)(2) of the
Code,
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
26
the issue price of the investment unit is the
purchase price of the Tranche B Note, with [*****] thereof
representing the fair market value of the Tranche B Warrant.
Unless otherwise required by Law, the Parties shall not take any
position inconsistent with these allocations on any tax return or
for any other tax purpose.
SECTION 5.07.
Registered Obligation .
(a)
Borrower shall establish and maintain at its address referred to in
Section 13.04 (A) a record of ownership (the “
Register ”) in which Borrower agrees to register by
book entry the interests (including any rights to receive payment
hereunder) of each Lender in the Loans, each of their obligations
under this Amended Agreement to participate in the Loans, and any
assignment of any such interest, obligation or right, and
(B) accounts in the Register in accordance with its usual
practice in which it shall record (1) the names and addresses
of the Lender(s) (and each change thereto pursuant to
Section 13.02), (2) the Tranche B Commitment of each
Lender, (3) the amount of the Loans and each funding of any
participation described in clause (A) above, (4) the
amount of any principal or interest due and payable or paid, and
(5) any other payment received and its application to the
Loans.
(b)
Notwithstanding anything to the contrary contained in this Amended
Agreement, the Loans (including any Note evidencing such Loan) are
registered obligations, the right, title and interest of the Lender
and its assignees in and to such Loans shall be transferable only
upon notation of such transfer in the Register and no assignment
thereof shall be effective until recorded therein. This
Section 5.07 and Section 13.02 shall be construed so that
the Loans are at all times maintained in “registered
form” within the meaning of Sections 163(f),
871(h)(2) and 881(c)(2) of the Code and any related
regulations (and any successor provisions).
ARTICLE VI
PAYMENTS; COMPUTATIONS
SECTION 6.01.
Making of Payments .
(a)
To the extent (i) that Applicable Included Receipts received
into the Lockbox Account during any fiscal quarter are less than
the total amount of Applicable Included Receipts required for
purposes of calculating the interest that Borrower is required to
pay to Lender under Section 4.01(a) on any Interest
Payment Date or (ii) Borrower exercises its option to pay any
Deficiency Amount out of other funds of Borrower and/or any of its
Subsidiaries as described in the last sentence of
Section 4.01(a), then such deficiency shall be made in
Dollars, by deposit in same day funds by 3:00 p.m. New York
time on the date the interest payment is due, to the Lockbox
Account, for the account of the applicable Lending Office(s), or to
any other account designated by the Lenders by Notice to
Borrower.
(b)
Notwithstanding anything to the contrary contained herein, any
payment stated to be due hereunder or under any Note on a given day
in a specified month shall be made or shall end (as the case may
be), (i) if there is no such given day or corresponding day,
on the last Business Day of such month or (ii) if such given
day or corresponding day is not a Business Day, on the next
succeeding Business Day, unless such next succeeding Business Day
falls in a
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
27
different calendar month, in which case such
payment shall be made on the next preceding Business
Day.
SECTION 6.02.
Setoff or Counterclaim . Each payment by Borrower
under this Amended Agreement or under any Note shall be made
without setoff or counterclaim. Lenders shall have the right
to setoff any and all amounts owed by Borrower and/or any of its
Subsidiaries under this Amended Agreement as provided in
Section 11.03.
ARTICLE VII
CLOSING DOCUMENTATION
SECTION 7.01.
Tranche A Loan Closing Documentation . In order
to induce the Lender to make the Tranche A Loan on the Closing
Date, the following documentation was provided simultaneous with
the execution of the Original Loan Agreement:
(a)
Borrower delivered to the Lender the Tranche A Note, dated the
Closing Date.
(b)
Borrower delivered to the Lender an executed copy of:
(i) a
certificate of Borrower, dated the Closing Date, substantially in
the form set forth in Exhibit L to the Original Loan
Agreement together with the attachments specified
therein;
(ii) an
opinion of Edwards Angell Palmer & Dodge LLP, counsel to
Borrower, dated the Closing Date, substantially in the form of
Exhibit M to the Original Loan Agreement and otherwise
in form and substance satisfactory to the Lender;
(iii) an opinion
of Wolf Greenfield, counsel of Borrower , dated the Closing Date,
substantially in the form of Exhibit N to the Original
Loan Agreement and otherwise in form and substance satisfactory to
the Lender.
(iv) an opinion of
Lowrie, Lando & Anasasi, LLP, counsel of Borrower, dated
the Closing Date, substantially in the form of
Exhibit O to the Original Loan Agreement and in form
and substance satisfactory to the Lender.
(c)
Borrower delivered to the Lender a certificate, dated the Closing
Date, of a senior officer of Borrower (the statements made in which
to have been true and correct on and as of the Closing Date):
(i) attaching copies, certified by such officer as true and
complete, of Borrower’s certificate of incorporation or other
organizational documents (together with any and all amendments
thereto) certified by the appropriate Governmental Authority as
being true, correct and complete copies; (ii) attaching
copies, certified by such officer as true and complete, of
resolutions of the Board of Directors of Borrower authorizing and
approving the execution, delivery and performance by Borrower of
the Original Loan Agreement, the other Original Transaction
Documents and the transactions
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
28
contemplated therein;
(iii) setting forth the incumbency of the officer or officers
of Borrower who executed and delivered the Original Loan Agreement
and the other Original Transaction Documents including therein a
signature specimen of each such officer or officers; and
(iv) attaching copies, certified by such officer as true and
complete, of certificates of the appropriate Governmental Authority
of the jurisdiction of formation, stating that Borrower was in good
standing under the laws of such jurisdiction as of the Closing
Date.
(d)
Borrower executed and delivered to the Lender the Original Loan
Documents and such other documents as the Lender reasonably
requested, in each case, in form and substance satisfactory to the
Lender.
(e)
Borrower executed and delivered to the Lender the Tranche A Warrant
Agreement.
(f)
Borrower executed and delivered to the Lender the other Original
Transaction Documents, which were in full force and
effect.
(g)
The Lender received all fees and expenses due and payable to the
Lender on the Closing Date under the Original Loan Agreement and
the other Original Transaction Documents.
(h)
No event occurred and continued that constituted a Default or an
Event of Default under the Original Loan Agreement or a similar
event under the other Original Transaction Documents and no such
event occurred or would have occurred by reason of the Tranche A
Loan.
(i)
The representations and warranties made by Borrower in
Article VIII of the Original Loan Agreement and in the other
Original Transaction Documents were true and correct as of the
Closing Date, before and after giving effect to the Tranche A
Loan.
(j)
Borrower delivered to the Lender true copies of the License
Agreements in existence as of the Closing Date, certified by an
officer of Borrower, including all amendments, supplements or other
modifications thereto which, as of the Closing Date, were in full
force and effect.
(k)
All filings, recordings and other actions that were necessary or
reasonably requested by the Lender in order to establish, protect,
preserve and perfect the security interest in the assets of
Borrower as provided in the Original Security Agreement as a valid
and perfected first priority security interest with respect to such
assets were duly effected.
(l)
All necessary governmental and third-party approvals, consents and
filings, including in connection with the Tranche A Loan, the
Original Security Agreement and the Tranche A Warrant Agreement
were obtained or made and be in full force and effect.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
29
(m)
The Lender had conducted a background check of the officers of
Borrower and the results were to the satisfaction of the
Lender. The Lender received all documentation and other
information required by bank regulatory authorities under
applicable “know your customer” and anti-money
laundering rules and regulations, including without
limitation, the Patriot Act, including, without limitation, the
information described in Section 13.19.
(n)
The Lender received from Borrower (i) an executed copy of the
Release of Security Agreement between Borrower and Paul Royalty
Funds Holdings II, (ii) evidence to the satisfaction of the
Lender that such release(s) in form and substance satisfactory
to the Lender were to be filed with the U.S. Patent and Trademark
Office and the U.S. Copyright Office on the Closing Date,
(iii) evidence to the satisfaction of the Lender that a UCC-3
termination statement was filed with the office of the Secretary of
State of the State of Delaware on the Closing Date, and
(iv) evidence to the satisfaction of the Lender of agreements
to terminate (A) the lockbox agreement among Paul Royalty
Funds Holdings II, Borrower and JP Morgan Chase Bank, and
(B) the escrow arrangement with respect to duplicate libraries
for the benefit of Paul Royalty Funds Holdings II.
SECTION 7.02.
Tranche B Loan Closing Documentation . In order to
induce the Lender to make the Tranche B Loan on the Tranche B
Funding Date, the following documentation was provided simultaneous
with the execution of this Amended Agreement:
(a)
Borrower executed and delivered to the Lender the Tranche B
Note.
(b)
Borrower delivered to the Lender an executed copy of:
(i) a
certificate of Borrower, dated the Tranche B Closing Date,
substantially in the form set forth in Exhibit G hereto
together with the attachments specified therein;
(ii) an
opinion of Edwards Angell Palmer & Dodge LLP, counsel to
Borrower, dated the Tranche B Closing Date, substantially in the
form of Exhibit H hereto and otherwise in form and
substance satisfactory to the Lender;
(iii) an opinion
of Wolf Greenfield, counsel of Borrower, dated the Tranche B
Closing Date, substantially in the form of Exhibit I
hereto and otherwise in form and substance satisfactory to the
Lender; and
(iv) an opinion of
Lowrie, Lando & Anasasi, LLP, counsel of Borrower, dated
the Tranche B Closing Date, substantially in the form of
Exhibit J hereto and in form and substance satisfactory
to the Lender.
(c)
Borrower delivered to the Lender a certificate, dated the Tranche B
Closing Date, of a senior officer of Borrower (the statements made
in which shall be true and correct on and as of the Tranche B
Closing Date): (i) attaching copies, certified by such
officer as true and complete, of Borrower’s certificate of
incorporation or other organiza-
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
30
tional documents (together with any
and all amendments thereto) certified by the appropriate
Governmental Authority as being true, correct and complete copies;
(ii) attaching copies, certified by such officer as true and
complete, of resolutions of the Board of Directors of Borrower
authorizing and approving the execution, delivery and performance
by Borrower of this Amended Agreement, the other Transaction
Documents and the transactions contemplated herein and therein;
(iii) setting forth the incumbency of the officer or officers
of Borrower who have executed and delivered this Amended Agreement
and the other Transaction Documents including therein a signature
specimen of each such officer or officers; and (iv) attaching
copies, certified by such officer as true and complete, of
certificates of the appropriate Governmental Authority of the
jurisdiction of formation, stating that Borrower is in good
standing under the laws of such jurisdiction.
(d)
Borrower executed and delivered to the Lender the Security
Agreement (including the schedules thereto) and such other
documents as the Lender reasonably requested, in each case, in form
and substance satisfactory to the Lender.
(e)
Borrower executed and delivered to the Lender the Tranche B Warrant
Agreement.
(f)
Borrower executed and delivered to the Lender the other Transaction
Documents, which were in full force and effect.
(g)
The Lender received all fees and expenses due and payable to the
Lender on or prior to the Tranche B Closing Date under this Amended
Agreement and the other Transaction Documents.
(h)
All filings, recordings and other actions that are necessary or
reasonably requested by the Lender in order to establish, protect,
preserve and perfect the security interest in the assets of
Borrower as provided in the Security Agreement as a valid and
perfected first priority security interest with respect to such
assets have been duly effected, including the filing of a UCC-3
financing statement amendment and a Patent Security Agreement (as
defined in the Security Agreement) and Copyright Security Agreement
(as defined in the Security Agreement) with respect to any
registered intellectual property Collateral which Lender has not
previously filed a Patent Security Agreement or Copyright Security
Agreement, with respect thereto.
(i)
Borrower delivered to the Lender true copies of the License
Agreements certified by an officer of Borrower, including all
amendments, supplements or other modifications thereto, and each
License Agreement and amendment, supplement or other modification
thereto shall be in full force and effect, provided that Borrower
was not required to deliver any License Agreements which were
delivered to Lender as of the Closing Date or in any Business
Report and that have not been amended, modified, supplemented or
terminated since the date they were so delivered.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
31
(j)
All necessary governmental and third-party approvals, consents and
filings, including in connection with the Tranche B Loan, the
Security Agreement and the Tranche B Warrant Agreement were
obtained or made and be in full force and effect.
ARTICLE VIII
REPRESENTATIONS AND WARRANTIES
SECTION 8.01.
Representations and Warranties of Borrower . Borrower
hereby represents and warrants to Lender as follows (with such
representations and warranties qualified to the extent of the
Schedules referred to therein and delivered to the Lender
concurrently with the execution and delivery of this Amended
Agreement):
(a)
Borrower is a corporation duly organized, validly existing and in
good standing under the laws of Delaware and is duly qualified as a
foreign corporation and, where legally applicable, is in good
standing in each jurisdiction in which such qualification is
required by law, other than those jurisdictions as to which the
failure to be so qualified or in good standing could not,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, and has the power and authority (including
any required license, permit or other approval from any
Governmental Authority) to own its assets, to carry on its business
as currently conducted and to consummate the transactions
contemplated in, and to perform its obligations under, this Amended
Agreement and the other Transaction Documents to which it is party
or by which it is bound.
(b)
Borrower has taken all necessary action to authorize its execution
and delivery of this Amended Agreement and the other Transaction
Documents to which it is party, the performance of its obligations
under this Amended Agreement and the other Transaction Documents to
which it is party or by which it is bound and the consummation of
the transactions contemplated hereby and thereby.
(c)
This Amended Agreement and each other Transaction Document to which
Borrower is party has been duly executed and delivered by Borrower,
and each constitutes a valid and binding obligation of Borrower,
enforceable against Borrower in accordance with its terms, subject
to applicable bankruptcy, insolvency, moratorium and similar laws
affecting creditors’ rights generally, and subject to general
principles of equity (regardless of whether enforcement is sought
in a proceeding in equity or at law).
(d)
No authorization or action of any kind by any Governmental
Authority is necessary to authorize the transactions contemplated
by this Amended Agreement and each other Transaction Document or
required for the validity or enforceability against Borrower of
this Amended Agreement and each other Transaction Document, except
any filings with a Governmental Authority required to perfect the
Lender’s security interest under the Security Agreement and
any filings with the United States Securities and Exchange
Commission (“ SEC ”).
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
32
(e)
No consent or approval of, or notice to, any Person is required by
the terms of any agreement, contract, lease, commitment, license
and other arrangement (each a “ Contract ”) for
the execution or delivery of, or the performance of the obligations
of Borrower under, this Amended Agreement and the other Transaction
Documents to which Borrower is party or the consummation of the
transactions contemplated hereby or thereby, and such execution,
delivery, performance and consummation will not result in any
breach or violation of, or constitute a default under Borrower
Documents or any material Contract, instrument or Law applicable to
Borrower, any of its Subsidiaries or any of its assets.
(f)
There are no actions, proceedings or claims pending or, to the
actual knowledge of Borrower, threatened the adverse determination
of which could reasonably be expected to have a Material Adverse
Effect.
(g)
No Default or Event of Default has occurred and is continuing, and
no such event will occur upon the making of the Loan.
(h)
The representations and warranties previously made by Borrower in
Article VIII of the Original Loan Agreement and in the other
Transaction Documents shall have been true and correct as of the
date such representations and warranties were made (in each case,
except to the extent such representations and warranties expressly
relate to an earlier date, in which case such representations and
warranties shall have been true and correct as of such earlier
date).
(i)
With respect to each Contract that is material to the conduct of
the LFRP, (i) each such Contract is a valid and binding
agreement and each such Contract is in full force and effect, and
(ii) Borrower and/or any of its Subsidiaries is in compliance
with each such Contract and has no actual knowledge of any default
under any such Contract which default has not been cured or
waived.
(j)
All written information heretofore, herein or hereafter supplied to
the Lender by or on behalf of Borrower in connection with the Loans
and the other transactions contemplated hereby has been, is and
will be accurate and complete in all material respects. All
representations and warranties made by Borrower in any of the other
Transaction Documents to which it is party are true and correct in
all material respects.
(k)
The Financial Statements are complete and accurate in all material
respects, were prepared in conformity with GAAP applied on a
consistent basis during the periods involved (except as may be
indicated in the notes thereto) and present fairly in all material
respects, in accordance with applicable requirements of GAAP, the
consolidated financial position and the consolidated financial
results of the operations of Borrower and its Subsidiaries as of
the dates and for the periods covered thereby and the consolidated
statements of cash flows of Borrower and its Subsidiaries for the
periods presented therein. Except as disclosed in
Borrower’s SEC filings, there have been no Material Adverse
Effects since December 31, 2008.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
33
(l)
Borrower and its Subsidiaries have no Indebtedness other than
(i) identified in the Financial Statements or
(ii) incurred by Borrower or its Subsidiaries in the ordinary
course of business since December 31, 2008 or
(c) otherwise listed and described on Schedule 8.01(l)
.
(m)
As of February 28, 2009 and after giving effect to the making
of the Loans:
(i)
The aggregate value of the assets of Borrower, at fair value and
present fair salable value, exceeds (i) its Liabilities and
(ii) the amount required to pay such Liabilities as they
become absolute and matured in the normal course of
business;
(ii)
Borrower has the ability to pay its debts and Liabilities as they
become absolute and matured in the normal course of business;
and
(iii) Borrower
does not have an unreasonably small amount of capital with which to
conduct its business.
(n)
Borrower’s Subsidiaries are set forth on Schedule
8.01(n) .
(o)
(i) Borrower and its Subsidiaries are in compliance with all
applicable Laws except where the failure to be in compliance could
not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. No prospective change in any
applicable laws, rules, ordinances or regulations has been proposed
or adopted which, when made effective, could individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(ii)
Borrower possesses all material certificates, authorizations and
permits issued or required by the appropriate federal, state, local
or foreign regulatory authorities, including any effective
investigational new drug application or its equivalent, necessary
to conduct the LFRP, including all such certificates,
authorizations and permits required by the FDA or any other
federal, state, local or foreign agencies or bodies engaged in the
regulation of pharmaceuticals or biohazardous substances or
materials except where the failure to possess such certificates,
authorizations and permits, individually or in the aggregate, could
not reasonably be expected to result in a Material Adverse
Effect. Borrower has not received any notice of proceedings
relating to, and to the Knowledge of Borrower there are no facts or
circumstances that could reasonably be expected to lead to, the
revocation, suspension, termination or modification of any such
certificate, authorization or permit.
(iii)
To the actual knowledge of Borrower, there has been no indication
that the FDA or any other Regulatory Agency has any material
concerns with any Product or may not approve any Product, nor has
any Product, to the actual knowledge of Borrower, suffered any
material adverse events in any clinical trial.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
34
(p)
Borrower is not an investment company subject to regulation under
the Investment Company Act of 1940.
(q)
Borrower has timely filed all tax returns required to be filed by
it and has paid all taxes due reported on such returns or pursuant
to any assessment received by Borrower, except for failures to file
tax returns or pay taxes that, individually, and in the aggregate,
are not reasonably expected to result in a Material Adverse
Effect. Any charges, accruals or reserves on the books of
Borrower in respect of taxes are adequate except for inadequacies
that, individually, and in the aggregate, are not reasonably
expected to result in a Material Adverse Effect. Borrower has
had no material liability for any taxes imposed on or with respect
to its net income (except for state or local income or franchise
taxes). Borrower has fulfilled all its obligations with
respect to withholding taxes except for failures that,
individually, and in the aggregate, are not reasonably expected to
result in a Material Adverse Effect. No deduction or
withholding for or on account of any tax has been made, or was
required under applicable Law to be made, from any payment to
Borrower under the License Agreements in effect on the Tranche B
Closing Date.
(r)
Neither Borrower nor any ERISA Affiliate has ever incurred any
unsatisfied liability or expects to incur any liability under Title
IV or Section 302 of ERISA or Section 412 of the Code or
any similar non-U.S. law or maintains or contributes to, or is or
has been required to maintain or contribute to, any employee
benefit plan (as defined in Section 3(3) of ERISA)
subject to Title IV or Section 302 of ERISA or
Section 412 of the Code or any non-U.S. law. The
consummation of the transactions contemplated by this Amended
Agreement will not constitute or result in any non-exempt
prohibited transaction under Section 406 of ERISA,
Section 4975 of the Code or substantially similar provisions
under any foreign or U.S. federal, state or local laws,
rules or regulations. Neither Borrower nor any of its
Subsidiaries has incurred any material liability with respect to
any obligation to provide benefits, including death or medical
benefits, with respect to any person beyond their retirement or the
termination of service other than coverage mandated by
law.
(s)
(i) Except as set forth on Schedule 8.01(s)(i) , all
of the LFRP Intellectual Property owned by Borrower is solely (and
not jointly) owned by Borrower and is free and clear of any and all
Liens, except those Liens created in favor of Lender pursuant to
the Transaction Documents. The Included Receipts and all of the
rights of Borrower under the In Licenses and License Agreements and
all other rights in and to the LFRP are free and clear of any and
all Liens, except those Liens created in favor of Lender pursuant
to the Transaction Documents.
(ii)
Borrower owns, and is the sole holder of, all the Included
Receipts. Borrower owns, and is the sole holder of, and/or
has and holds a valid, enforceable and subsisting license to, all
assets (including LFRP Intellectual Property) that are required to
produce or receive any payments from any Contract Party or payor
under and pursuant to, and subject to the terms of any License
Agreements. Borrower has not transferred, sold,
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
35
or otherwise disposed of, or agreed
to transfer, sell, or otherwise dispose of any portion of its
respective rights to receive payment of Royalties. Except as
set forth on Schedule 8.01(s)(ii) , no Person other than
Borrower has any right to receive the payments payable under any
License Agreement entered into from and after the Closing Date
through Tranche B Closing Date, other than, in respect of the
Included Receipts, Lender.
(t)
The claims and rights of the Lender created by this Amended
Agreement and any other Transaction Document in and to the
Collateral is senior to any Indebtedness or other obligation of
Borrower, with respect to such Collateral.
(u)
Borrower’s principal place of business and chief executive
office are set forth on Schedule 8.01(u) .
(v)
(i) Borrower has provided Lender all material information in
its possession, or otherwise known to it with respect to the LFRP
Patents.
(ii)
Schedule 8.01(v)(ii) sets forth an accurate and
complete list of all LFRP Patents (including all LFRP Patents not
owned by Borrower). For each item of the LFRP Patents listed
on Schedule 8.01(v)(ii) , Borrower has indicated
(A) the countries in each case in which such item is patented,
registered or in which an application for patent or registration is
pending, (B) the application numbers, (C) the
registration or patent numbers, (D) the scheduled expiration
date of the issued patents, and (E) the owner of such item of
LFRP Patents.
(iii)
The issued LFRP Patents owned by Borrower are valid, enforceable
and subsisting. To the Knowledge of Borrower, each individual
associated with the filing and prosecution of the LFRP Patents
owned by Borrower, including the named inventors of such LFRP
Patents, has complied in all material respects with all applicable
duties of candor and good faith in dealing with any Patent Office,
including any duty to disclose to any Patent Office all information
known to be material to the patentability of each of such LFRP
Patents, in those jurisdictions where such duties exist.
[*****].
(iv)
Schedule 8.01(v)(iv) sets forth an accurate and
complete list of all LFRP Patents owned by Borrower that have
issued with at least one claim covering the Company LFRP Methods
and Libraries.
(v)
Borrower has not sold or otherwise transferred any patents or
patent applications that have issued or may issue with at least one
claim covering the Company LFRP Methods and Libraries or falling
within the scope of the patents licensed under the Patent License
Agreements.
(vi)
There are no unpaid maintenance or renewal fees payable by Borrower
to any third party that are currently overdue for any of the LFRP
Patents or other LFRP Intellectual Property owned by
Borrower. To the Knowledge of Borrower no material
ap-
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
36
plications for LFRP Patents owned by
Borrower in whole or in part have lapsed or been abandoned,
cancelled or expired.
(vii)
Borrower has not undertaken and, to the Knowledge of Borrower, no
licensee has undertaken or omitted to undertake any acts, and no
conduct, circumstances or grounds exist that would void, invalidate
or eliminate, in whole or in part, the enforceability of any of the
LFRP Intellectual Property. [*****]
(viii)
Except as set forth on Schedule 8.01(v)(viii) , Borrower has
not received or otherwise been the beneficiary of any written
opinions of counsel with respect to infringement, non-infringement
or invalidity of third party intellectual property with respect to
the Company LFRP Methods and Libraries that are not the subject of
an In License.
(ix)
Except as set forth on Schedule 8.01(v)(ix) , to the
Knowledge of Borrower there is, and has been, no pending, decided
or settled opposition, interference, reexamination, injunction,
claim, lawsuit, proceeding, hearing, investigation, complaint,
arbitration, mediation, demand, International Trade Commission
investigation, decree, or any other dispute, disagreement, or claim
(collectively referred to hereinafter as “ Disputes
”), nor, to the Knowledge of Borrower, has any such Dispute
been threatened, challenging the scope, legality, validity,
enforceability or ownership of any LFRP Intellectual Property or
which would give rise to a credit against the payments due to
Borrower from the applicable License Agreements for the use of the
related licensed LFRP Intellectual Property, and no such scheduled
Dispute is (or would be if adversely determined) material to the
LFRP.
(x)
To the Knowledge of Borrower, there are no Disputes by any third
party against Borrower, any licensor under an In License or any
licensee under a License Agreement relating to the LFRP.
Borrower has not received or given, and to the Knowledge of
Borrower, no such licensee or licensor has received or given any
notice of any such Dispute and, to the Knowledge of Borrower, there
exist no circumstances or grounds upon which any such claim could
be asserted. [*****].
(xi)
There is no pending or, to the Knowledge of Borrower, threatened
action, suit, or proceeding, or any investigation or claim by any
Governmental Authority to which Borrower or, to the Knowledge of
Borrower, to which any licensee under any License Agreement or any
party to a In License is a party (i) that would be the subject
of a claim for indemnification, if any, by or against Borrower or
(ii) that the Company LFRP Methods and Libraries do or will
infringe on any patent or other intellectual property rights of any
other Person. [*****].
(w)
(i) Schedule 8.01(w)(i) sets forth an accurate
and complete list of all agreements relating to LFRP in the
following categories whether oral or written ( provided such
oral agreements are to the Knowledge of Borrower):
manufacturing and supply agreements, In Licenses and License
Agreements, options (not part of License
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
37
Agreements or In Licenses),
agreements not to enforce (not part of License Agreements or In
Licenses), consents, settlements, assignments, security interests,
liens and other encumbrances or mortgages, and any amendment(s),
renewal(s), novation(s) and termination(s) pertaining
thereto, true and correct copies of which have been provided to
Lender. For each agreement specified on Schedule
8.01(w)(i) , Borrower has indicated (A) whether such
agreement relates to inbound licenses of LFRP Intellectual Property
to Borrower or outbound licenses of LFRP Intellectual Property by
Borrower and (B) the specific LFRP Intellectual Property
relating to such agreement. Each agreement specified on
Schedule 8.01(w)(i) , whether or not terminated prior to the
Tranche B Closing Date, constitutes a valid and binding obligation,
enforceable in accordance with its terms, subject, as to
enforcement of remedies, to bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights
generally or general equitable principles. Borrower is not in
breach of such agreements and, to the Knowledge of Borrower, no
circumstances or grounds exist that would give rise to a claim of
breach or right of rescission, termination (other than existing
rights under any License Agreement for a party to terminate for
convenience), revision, or amendment of any of the agreements
specified on Schedule 8.01(w)(i) , including the signing of
this Amended Agreement. None of the Excluded Agreements fall
within the scope of an In License or License Agreement as each is
defined; provided that the intellectual property or
technology which is the subject of an In License may be assigned in
connection with an Excluded Agreement. None of the Excluded
Agreements was used in the calculation of the revenue forecasts
provided by Borrower to Lender on February 13,
2009.
(ii)
With respect to the License Agreements and In Licenses, there has
been no correspondence or other written or, to the Knowledge of
Borrower, oral communication sent by or on behalf of Borrower to,
or received by or on behalf of Borrower from, any Contract Party,
the subject matter of which could, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(iii)
Except as set forth on Schedule 8.01(w)(iii) , each such
License Agreement or In License is in full force and effect and has
not been impaired, waived, altered or modified in any respect,
whether by consent or otherwise, and no scheduled item could,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.
(iv)
The Contract Party under each such License Agreement or In License
has not been released, in whole or in part, from any of its
obligations under such License Agreement.
(v)
Borrower has not received (A) any notice or other written or,
to the Knowledge of Borrower, oral communication of any Contract
Party’s intention to terminate such License Agreement or In
License in whole or in part, or consideration of any such
termination, or (B) except as set forth on Schedule
8.01(w)(v) , any notice or other written or, to the Knowledge
of Borrower, oral communication requesting any amendment,
alteration or modification of such License Agreement or In License
or any subli-
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
38
cense or assignment thereunder, and
no scheduled item could, individually or in the aggregate,
reasonably be expected to have a Material Adverse
Effect.
(vi)
To the Knowledge of Borrower, nothing has occurred and no condition
exists that would adversely impact the right of Borrower to receive
any payments payable under any License Agreement except where such
occurrence or condition could not reasonably be expected to result
in a Material Adverse Effect. Other than as set forth on
Schedule 8.01(w)(vi) , Borrower, or, to the Knowledge of
Borrower, any Contract Party has not taken any action or omitted to
take any action, that would adversely impact the right of Lender to
take a security interest in the LFRP Technology, and no scheduled
item could, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.
(vii)
[*****].
(viii)
Except as set forth on Schedule 8.01(w)(viii) , no License
Agreement has been satisfied in full, discharged, canceled,
terminated, subordinated or rescinded, in whole or in part.
Each License Agreement is the entire agreement between the parties
thereto relating to the subject matter thereof, and no scheduled
item could, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.
(ix)
The execution, delivery and performance of each License Agreement
and In License was and is within the corporate powers or other
organizational power of Borrower and, to the Knowledge of Borrower,
the Contract Party thereto. Each License Agreement and In
License was duly authorized by all necessary action on the part of,
and validly executed and delivered by, Borrower and, to the
Knowledge of Borrower, the Contract Party thereto. There is
no breach or default, or event which upon notice or the passage of
time, or both, could give rise to any breach or default, in the
performance of such License Agreement or In License by Borrower or,
to the Knowledge of Borrower, the Contract Party
thereto.
(x)
The representations and warranties made in each existing Material
License and In License by Borrower were as of the date made true
and correct in all material respects except where the failure to be
true and correct could not reasonably be expected to have a
Material Adverse Effect.
(xi)
The royalty rates and the duration of such royalty rates in each
country under each existing License Agreement are as set forth on
Schedule 8.01(w)(xi) . There are no royalties due to
Contract Parties under In Licenses with respect to Royalties under
the License Agreements except to [*****].
(xii)
[*****].
(xiii)
No software is necessary for use in the LFRP other than
commercially available software.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
39
(xiv)
Schedule C sets forth all the biological material, know-how,
data, technical and other information other than the LFRP Libraries
described in Schedule D that is provided to Contract Parties
under Library License Agreements, other than in oral
form.
(xv)
The LFRP Libraries described in Schedule D are all the
libraries used in the LFRP within the twelve (12) months prior to
the Closing Date with the exception of affinity maturation
libraries.
(x)
Borrower and Borrower’s Subsidiaries have the insurance
policies with the coverages and limits set forth on Schedule
8.01(x) , carried with the insurance companies also set forth
therein.
SECTION 8.02.
Survival of Representations and Warranties . All
representations and warranties of Borrower contained in this
Amended Agreement shall survive the execution, delivery and
acceptance thereof by the Parties and the closing of the
transactions described in this Amended Agreement.
ARTICLE IX
AFFIRMATIVE COVENANTS
SECTION 9.01.
Maintenance of Existence . Borrower and/or any of its
Subsidiaries party to the Loan Documents shall at all times
(a) preserve, renew and maintain in full force and effect its
legal existence and good standing as a corporation under the Laws
of the jurisdiction of its organization; (b) not change its
name or its chief executive office as set forth herein without
having given the Lender simultaneous notice thereof; (c) take
all reasonable action to maintain all rights, privileges, permits,
licenses and franchises necessary or desirable in the normal
conduct of its business, except to the extent that failure to do so
could not reasonably be expected to have a Material Adverse Effect;
and (d) preserve or renew all LFRP Intellectual Property, the
non-preservation of which could reasonably be expected to have a
Material Adverse Effect.
SECTION 9.02.
Use of Proceeds . Borrower shall use the net proceeds
of the Loans received by it (i) for general corporate purposes
and/or (ii) to pay all fees and expenses payable by Borrower
pursuant to the Transaction Documents.
SECTION 9.03.
Financial Statements and Information .
(a)
In the event that any such information need not to be filed with
the SEC pursuant to Section 13 or 15(d) of the Exchange
Act, Borrower shall furnish to the Lender, on or before the
forty-fifth day after the close of each quarter of each fiscal
year, the unaudited consolidated balance sheet of Borrower as at
the close of such quarter and unaudited consolidated statement of
operations and comprehensive loss and cash flows of Borrower for
such quarter, duly certified by the chief financial officer of
Borrower as having been prepared in accordance with GAAP.
Concurrently with the delivery or filing of the documents described
in the preceding sentence, Borrower shall furnish to the Lender a
certificate of the chief financial officer, chief accounting
officer or treasurer of Borrower, which certificate shall include a
statement that
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
40
such officer has no knowledge, except as
specifically stated, of any condition, event or act which
constitutes a Default or Event of Default.
(b)
In the event that any such information need not be filed with the
SEC pursuant to Section 13 or 15(d) of the Exchange Act,
Borrower shall furnish to the Lender, on or before the sixtieth day
after the close of each fiscal year, Borrower’s audited
financial statements as at the close of such fiscal year, including
the consolidated balance sheet as at the end of such fiscal year
and consolidated statement of operations and cash flows of Borrower
for such fiscal year, in each case accompanied by the report
thereon of independent registered public accountant of nationally
recognized standing. Concurrently with the delivery or filing
of the documents described in the preceding sentence, Borrower
shall furnish to the Lender a certificate of the chief financial
officer, chief accounting officer or treasurer of Borrower, which
certificate shall include a statement that such officer has no
knowledge, except as specifically stated, of any condition, event
or act which constitutes a Default or Event of Default.
(c)
Borrower shall, promptly upon receipt thereof, forward or cause to
be forwarded to the Lender copies of all notices, reports, updates
and other information regarding the License Agreements and Included
Receipts received from the Contract Parties which could reasonably
be expected to have a Material Adverse Effect.
(d)
Borrower shall furnish or cause to be furnished to the Lender from
time to time such other information regarding the financial
position, assets or business of Borrower or any other Subsidiary or
its compliance with any Transaction Document to which it is a party
or the LFRP as the Lender may from time to time reasonably
request.
(e)
Borrower shall, promptly after the end of each fiscal quarter of
Borrower (but in no event later than [*****] following the end of
such quarter), produce and deliver to the Lender a Quarterly Report
and Business Report for such quarter, together with a certificate
of a senior officer of Borrower, certifying that to the Knowledge
of Borrower that such Quarterly Report and Business Report are
true, correct and accurate in all material respects.
Following
receipt of any Business Report, the Lenders shall have the right to
require a meeting in person or by phone with management of Borrower
to discuss matters related to the LFRP. With each Quarterly
Report, Borrower shall provide a copy to the Lenders of each new
executed License Agreement, In License and a copy of any amendment
or other action (and notification of any action not in writing) as
described in Section 9.15.
SECTION 9.04.
Books and Records . Borrower shall keep proper books,
records and accounts in which entries in conformity with sound
business practices and all requirements of Law applicable to it
shall be made of all dealings and transactions in relation to its
business, assets and activities and as shall permit the preparation
of the consolidated financial statements of Borrower in accordance
with GAAP.
SECTION 9.05.
Inspection Rights; Access . Borrower shall, on
[*****], or, at any time during which a Default or Event of Default
shall have occurred and be continuing, permit representatives of
the Lender to examine its or its Subsidiaries’ assets, books
and records
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
41
upon reasonable Notice during normal business
hours. Borrower shall allow the Lender reasonable access to
its managers and/or officers. To the extent any License
Agreement contains provisions requiring confidential treatment of
any information, including financial information, that would
prohibit Borrower from providing such information to the Lender, in
connection with any audit permitted hereunder, Borrower shall have
its independent certified public accountants provide a summary of
the relevant information and certify that such information is true
and correct in all respects.
SECTION 9.06.
Maintenance of Insurance and Properties . Borrower and
its Subsidiaries shall maintain and preserve all of its properties
that are used and useful in the conduct of the LFRP in good working
order and condition, ordinary wear and tear excepted.
Borrower shall maintain insurance policies with the same or better
coverages and limits as those set forth on Schedule 8.01(x)
with the insurance companies set forth therein (the “
Insurance Providers ”) or with insurance companies
rated at least as high as the Insurance Providers as of the Closing
Date (according to A.M. Best Company, Inc.).
Borrower shall furnish to the Lender from time to time upon written
request full information as to the insurance carried.
SECTION 9.07.
Governmental Authorizations . Borrower shall obtain,
make and keep in full force and effect all authorizations from and
registrations with Governmental Authorities that may be required
for the validity or enforceability against Borrower of this Amended
Agreement and the other Transaction Documents to which it is a
party.
SECTION 9.08.
Compliance with Laws and Contracts .
(a)
Borrower and any its Subsidiaries shall comply with all applicable
Laws and perform its obligations under all Contracts relative to
the conduct of its business, including the Transaction Documents to
which it is party in all material respects.
(b)
Borrower shall at all times comply with the margin requirements set
forth in Section 7 of the Exchange Act and any regulations
issued pursuant thereto, including, without limitation, Regulations
T, U and X of the Board of Governors of the Federal Reserve System,
12 C.F.R., Chapter II.
SECTION 9.09.
Plan Assets . Borrower shall not take any action that
causes its assets to be deemed to be Plan Assets at any
time.
SECTION 9.10.
Notices .
(a)
Borrower shall promptly give written Notice to the Lender of each
Default or Event of Default and each other event that has or could
reasonably be expected to have a Material Adverse Effect;
provided that in any situation where Borrower knows a press
release or other public disclosure is to be made, Borrower shall
use all commercially reasonable efforts to provide such information
to the Lender as early as possible but in no event later than
simultaneously with such release or other public
disclosure.
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
42
(b)
Borrower shall promptly give written Notice to the Lender upon
receiving notice, or otherwise becoming aware, of any default or
event of default under the License Agreements.
(c)
Borrower shall, promptly after becoming aware thereof, give written
Notice to the Lender of any litigation or proceedings to which
Borrower or any of its Subsidiaries is a party or which could
reasonably be expected to have a Material Adverse
Effect.
(d)
Borrower shall, promptly after becoming aware thereof, give written
Notice to the Lender of any litigation or proceedings challenging
the validity of the License Agreements, the LFRP Intellectual
Property or any of the transactions contemplated
therein.
(e)
Borrower shall, promptly after becoming aware thereof, give written
Notice to the Lender of any representation or warranty made or
deemed made by Borrower in any of the Transaction Documents or in
any certificate delivered to the Lender pursuant hereto shall prove
to be untrue, inaccurate or incomplete in any material respect on
the date as of which made or deemed made.
SECTION 9.11.
Payment of Taxes . Borrower shall pay all material
taxes of any kind imposed on or in respect of its income or assets
before any penalty or interest accrues on the amount payable and
before any Lien on any of its assets exists as a result of
nonpayment except as provided in Section 10.03 hereof
and except for taxes contested in good faith by appropriate
proceedings and for which adequate reserves are maintained in
accordance with GAAP.
SECTION 9.12.
Waiver of Stay, Extension or Usury Laws . Borrower
will not at any time, to the extent that it may lawfully not do so,
insist upon, or plead, or in any manner whatsoever claim or take
the benefit or advantage of, any stay or extension law or any usury
law or other law that would prohibit or forgive Borrower from
paying all or any portion of the principal of or premium, if any,
or interest on the Loans as contemplated herein, wherever enacted,
now or at any time hereafter in force, or that may affect the
covenants or the performance of this Amended Agreement; and, to the
extent that it may lawfully do so, Borrower hereby expressly waives
all benefit or advantage of any such law and expressly agrees that
it will not hinder, delay or impede the execution of any power
herein granted to the Lender, but will suffer and permit the
execution of every such power as though no such law had been
enacted.
SECTION 9.13.
Additional Covenants of Borrower .
SECTION 9.14.
[*****]
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
43
SECTION 9.15.
Further Assurances . Borrower shall promptly, at its
sole cost and expense, execute and deliver to the Lender such
further instruments and documents, and take such further action, as
the Lender may, at any time and from time to time, reasonably
request in order to carry out the intent and purpose of this
Amended Agreement and the other Transaction Documents to which it
is a party and to establish and protect the rights, interests and
remedies created, or intended to be created, in favor of the Lender
hereby and thereby. [*****] In the event
that any of the Collateral is, directly or indirectly, sold,
leased, licensed, transferred or otherwise disposed of to a
Subsidiary of Borrower (other than in connection with a Permitted
Collateralization), Borrower shall cause such Subsidiary to execute
a joinder to the Security Agreement confirming that the Collateral
continues to be subject to the Lien granted to the Lender
thereunder and such other documentation that the Agent shall
reasonably request.
ARTICLE X
NEGATIVE COVENANTS
SECTION 10.01.
Activities of Borrower .
(a)
Neither Borrower nor any of its Subsidiaries shall amend, modify or
waive or terminate any provision of, or permit or agree to the
amendment, modification, waiver or termination of any provision of,
any of the Loan Documents, License Agreements or any material
Contract related to the LFRP that could reasonably be expected to
have a Material Adverse Effect without the prior written consent of
the Agent.
(b)
Neither Borrower nor any of its Subsidiaries shall use any current
or future protein, peptide or antibody selection technology to
establish a business or business unit competing with the LFRP or
enable a third party to use for funded research or license out any
such technology in a way that would compete with the
LFRP.
SECTION 10.02.
Merger; Sale of Assets .
(a)
Borrower shall not merge or consolidate with or into (whether or
not Borrower is the Surviving Person) any other Person and Borrower
will not, and will not cause or permit any Subsidiary to, sell,
convey, assign, transfer, lease or otherwise dispose of all or
substantially all of Borrower’s and its Subsidiaries assets
(determined on a consolidated basis for Borrower and its
Subsidiaries) to any Person in a single transaction or series of
related transactions, unless (1) either (A) Borrower will
be the Surviving Person or (B) the Surviving Person (if other
than Borrower) will be an entity organized and validly existing
under the laws of Delaware, and will, in any such case, expressly
assume the due and punctual payment of the principal of, premium,
if any, and interest on the Loans and the performance and
observance of every covenant of the Loan Documents to be performed
or observed on the part of Borrower and shall use its commercially
reasonable efforts to actively market and promote the LFRP and to
seek out and exploit opportunities for entering into Future
Licenses; and (2) immediately thereafter, on a pro forma basis
after giving effect to such transaction (and treating any
Indebtedness not previously an obligation of Borrower or any
Subsidiary of Borrower in connection with or as a result
of
Confidential materials omitted
and filed separately with the Securities and Exchange
Commission. Asterisks denote such omission.
44
such transaction as having been incurred at the
time of such transaction), no Default or Event of Default will have
occurred and be continuing.
(b)
Neither Borrower nor any of its Subsidiaries shall directly or
indirectly sell, lease, license, transfer or otherwise dispose of
all or any part of its assets consisting of or used in the LFRP
Technology or the LFRP, except (i) licenses of intellectual
property rights of Borrower or any of its Subsidiaries in
connection with services provided by Borrower or such Subsidiary
for fair value in an arm’s-length transaction in the ordinary
course of its business; (ii) sales of equ